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Introduzione: Il Glioblastoma (GBM) rappresenta il tumore astrocitico più 
aggressivo negli adulti, esibisce una prognosi infausta correlata alla resistenza alla 
terapia, che è principalmente focalizzata sull'uso della TMZ e della radioterapia 
(protocollo Stupp). Tra i fattori cruciali che sono coinvolti nella resistenza al 
trattamento con la TMZ emerge HIF-1α, che attiva diversi meccanismi tra cui 
angiogenesi ed EMT. Oltre alla sua primaria azione alchilante, la TMZ può esercitare 
altri effetti secondari dentro le cellule, come il rilascio delle ROS dai mitocondri 
mediato dallo stress del RE e l’attivazione dell’autofagia. Diversi lavori hanno 
riportato la degradazione di HIF-1α nei lisosomi attraverso l’autofagia chaperon-
mediata (CMA). L’importanza di questo potenziale terapeutico indiretto deve ancora 
essere dedotta, ma la comprensione dei principali meccanismi sta conferendo una 
nuova luce alle strategie di resistenza al tumore. Allo stesso tempo, nuove procedure 
atte a migliorare i trattamenti di radioterapia potrebbero essere utili per lo sviluppo 
di approcci maggiormente mirati.  
Scopo del lavoro: I principali obiettivi di questo progetto di ricerca sono stati: la 
comprensione dei meccanismi molecolari che sottendono alla resistenza del GBM 
alla TMZ, l’analisi del ruolo di HIF-1α nella resistenza e la valutazione di una nuova 
strategia atta a ripristinare la sensibilità al trattamento. Inoltre, data la necessità di 
un modello murino di GBM resistente per testare l’efficacia della nuova strategia 
terapeutica, un altro obiettivo di questo progetto è stato quello di utilizzare lo stesso 
modello ortotopico per sviluppare una procedura non invasiva per valutare il GBM 
tramite la PET utilizzando la 18F-Fluciclovine, la cui diffusione cellulare dipende dal 
grado di attività dei trasportatori amminoacidici (ASCT2). 
Materiali e metodi: Il ruolo cruciale dell’attività di HIF-1α nella risposta al 
trattamento con la TMZ è stato valutato caratterizzando due linee cellulari di GBM 
umano, le U251 sensibili alla TMZ e le T98 resistenti al farmaco, mediante saggi 
molecolari, biochimici, di espressione genica, mediante silenziamento genico ed 
inibizione farmacologica mediata dal PX-478. È stato valutato anche il 
coinvolgimento della CMA nella risposta alla TMZ caratterizzando, seguendo 
l’approccio sperimentale sopra riportato per HIF-1α e mediante analisi biochimiche 
e di proteine coinvolte in questo pathway. Il contributo delle ROS mitocondriali e il 
ruolo del macchinario di detossificazione delle ROS nel trattamento con la TMZ sono 
stati studiati, rispettivamente, trattando le cellule con il MitoT utilizzando tutte le 
tecniche menzionate sopra (includendo lo scratch test), e mediante Il profilo di 
espressione genica e le analisi di proteine. I trattamenti con H2O2, che seguono 
l’approccio sperimentale usato per il MitoT, sono stati utilizzati per testare il 
potenziale ruolo delle ROS nel ripristinare la resistenza alla TMZ. La linea cellulare 
di glioma murino CT-2A, dopo essere stata caratterizzata come le U251 e le T98 per 
valutare la responsività alla TMZ, sono state inoculate i.c. in topi C57BL/6J per 
sviluppare modelli ortotopici di glioma. Le acquisizioni MRI sono state fatte ai giorni 
9 e 15 dopo l'impianto per monitorare la crescita del tumore. La MRI è servita anche 
per monitorare la crescita del tumore in seguito alla radioterapia (15Gy-hemibrain). 
La PET con la 18F-Fluciclovine è stata fatta 16 giorni dopo l'impianto. I cervelli dei 
topi trattati e non trattati con la RT sono stati raccolti per successive analisi IHC 
riguardanti i livelli di espressione di ASCT2. 
Risultati: Questo studio ha permesso di identificare i biomarcatori di risposta e quei 
meccanismi coinvolti nella resistenza del GBM al trattamento con TMZ. HIF-1α è 
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stato individuato come il fattore cruciale di resistenza alla TMZ: le cellule ipossiche 
sono caratterizzate da una minore sensibilità al farmaco, mentre dopo trattamento, 
nelle cellule sensibili, è stata osservata una diminuzione sia nella vitalità che 
nell’attività di HIF-1α, invece nelle cellule resistenti non si è registrata alcuna 
modulazione né per la vitalità né per l’attività di HIF-1α. Questi risultati sono stati 
confermati dal profilo di espressione dei geni correlati all’apoptosi, CMA ed EMT. 
Ulteriori risultati hanno dimostrato il coinvolgimento della CMA nella degradazione 
di HIF-1α e la conseguente citotossicità dovuta al farmaco: infatti, il silenziamento di 
LAMP-2A ha indotto la resistenza nelle cellule precedentemente sensibili, mentre il 
silenziamento genico di HIF-1α ha ripristinato il fenotipo sensibile nelle T98 in 
precedenza resistenti. Anche l'annullamento dell’attività di HIF-1α mediata dal PX-
478 ha confermato il risultato precedente. Inoltre, l’attivazione della CMA che segue 
il trattamento con la TMZ può essere indotta dal rilascio delle ROS dai mitocondri 
come dimostrato utilizzando il MitoT. Inoltre, lo studio sul sistema di detossificazione 
delle ROS ha mostrato una sua down-regolazione nelle cellule sensibili dopo 
trattamento con TMZ, coerentemente alla fluttuazione temporanea delle ROS. Per 
di più, un aumento esogeno nei livelli di ROS intracellulari indotto dal trattamento 
con H2O2 ha prodotto gli stessi meccanismi attivati dalla TMZ nelle cellule sensibili 
dopo il rilascio delle ROS, determinando un profilo sensibile sia nelle cellule 
responsive che resistenti. Il profilo di espressione dei geni correlati alla CMA, 
all'apoptosi e a EMT è stato significativamente modificato in relazione all’apparente 
sensibilità, delucidando il ruolo cruciale delle ROS nel citoplasma ma anche 
l’importanza della CMA nel mediare l'effetto tossico della TMZ. Da notare, qui 
riportiamo che solo il trattamento combinato con H2O2 e TMZ ha significativamente 
indotto un profilo totalmente responsivo nelle cellule resistenti, mostrando il ruolo 
cruciale delle ROS, CMA, della modulazione di HIF-1α e del farmaco. Il risultato 
finale di questo lavoro è stato lo sviluppo di un modello murino ortotopico resistente 
alla TMZ inoculando mediante stereotassi (i.c.) le cellule murine CT-2A. Questo 
modello è risultato essere responsivo alla RT, come riportato dagli studi di MRI. Il 
tracciante 18F-Fluciclovine è stato utilizzato per monitorare la grandezza del tumore 
in vista di una sua implementazione nella valutazione della risposta al trattamento 
tramite PET. Alla fine, dati preliminari IHC di cervelli di topo non trattati e trattati con 
RT hanno confermato la down-regolazione dell’espressione di ASCT2 nei topi trattati 
rispetto a quelli non trattati. 
Conclusioni: In questo lavoro di tesi è stato dimostrato che l'attività di HIF-1α ha un 
ruolo chiave nella resistenza alla TMZ, che la CMA ha un ruolo cruciale nel mediare 
la citotossicità indotta dal farmaco e che l’induzione di questo pathway è dovuta a 
un incremento transitorio del livello di ROS intracellulari. Inoltre, un incremento 
esogeno dei livelli intracellulari di ROS ha ripristinato un profilo completamente 
sensibile nelle cellule resistenti, aprendo la strada per la valutazione di nuovi 
approcci terapeutici.  I modelli ortotopici murini di CT-2A rappresentano una buona 
opportunità per la valutazione in vivo di questi nuovi trattamenti, in particolare 
utilizzando un imaging multimodale non invasivo, strategia discussa in questo 
lavoro. 
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Background: Glioblastoma (GBM) represents the most aggressive astrocytic brain 
tumour in adults and exhibits a dismal prognosis related to resistance to therapy, 
which is principally based on Temozolomide plus RT (Stupp protocol). Among crucial 
factors which are involved in resistance to TMZ treatment, HIF-1α emerges since it 
activates several pathways, among which angiogenesis and EMT. Beyond its 
primary alkylating power, TMZ can exerts other secondary effects within cells, as ER 
stress-mediated ROS release from mitochondria and activation of autophagy. 
Several works have described HIF-1α degradation in lysosomes through the 
chaperone mediated autophagy (CMA) pathway. Importance of this indirect 
therapeutic potential has to be yet fully elucidated but the comprehension of the main 
mechanisms is shedding new light on tumour resistance strategies. At the same 
time, new procedures for the improvement of radiotherapy treatments could help the 
development of more precise approaches. 
Aims: The main purposes of this research project have been: to understand the 
molecular mechanisms underlying GBM resistance to TMZ, to investigate HIF-1α 
role in resistance and to assess a new strategy able to restore sensitivity to this 
treatment. Moreover, since the need for a murine model of resistant GBM to test the 
efficacy of the new therapeutic strategy, a secondary aim of this project has been 
the setting up of an orthotopic model of GBM, resistant to TMZ, and to characterize 
it as regards its radio-responsiveness. Final aim of the study has been to use the 
same orthotopic model to set up a non-invasive procedure to assess GBM by means 
of PET using 18F-Fluciclovine, whose cellular uptake is dependent upon the rate of 
activity of amino acid transporters (ASCT2). 
Materials and methods: HIF-1α activity crucial role in responsiveness to TMZ has 
been evaluated characterising two human GBM cell lines, U251-responsive cells to 
TMZ and T98-resistant ones, through molecular, biochemical ang gene expression 
analyses, by means of gene silencing and PX-478-mediated pharmacological 
inhibition. Moreover, CMA engagement in responsiveness to TMZ has been 
evaluated, following the experimental approach used for HIF-1α and through 
biochemical and protein studies of CMA pathway. Mitochondrial ROS contribution 
and the detox machinery role in TMZ treatment have been investigated, respectively, 
treating cells with MitoT utilising all the aforementioned techniques (including scratch 
test) and by means of gene expression profile and protein analyses. H2O2 
treatments, which retrace the experimental approach used for MitoT, have been 
used for testing the potential ROS role in reverting resistance to TMZ. Murine glioma 
cell line CT-2A, after having been characterised as U251 and T98 for evaluating its 
responsiveness to TMZ, have been stereotaxically injected (i.c.) in C57BL/6J mice 
to set up orthotopic glioma models. MRI scans have been carried out at days 9 and 
15 after i.c. injection for monitoring tumour growth. MRI has been exploited also for 
monitoring tumour growth after RT (15Gy-hemibrain). 18F-Fluciclovine-PET has been 
performed 16 days after i.c. injection. Untreated and RT-treated mice brains have 
been collected for IHC analyses regarding ASCT2 expression levels. 
Results: This study allowed the identification of response biomarkers and 
mechanisms involved in GBM resistance to TMZ treatment. HIF-1α has been 
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identified as a crucial factor in resistance to TMZ: hypoxic cells are characterized by 
a lower sensitivity to the drug, while a significant decrease both in viability and HIF-
1α activity has been detected after treatment in sensitive cells while no modulation 
in HIF-1α activity and viability was observed in T98 resistant cells. These results 
were confirmed by assessing also apoptosis-, CMA- and EMT-related gene 
expression. Further results showed the involvement of CMA in HIF-1α degradation 
and the consequent cytotoxicity due to the drug: in fact, LAMP-2A silencing induced 
resistance in previously sensitive cells, while HIF-1α gene silencing reverted T98 
phenotype from a previously resistant to a sensitive one. Also, the PX-478 mediated 
HIF-1α activity abrogation confirmed the previous result. CMA activation following 
TMZ treatment can be induced by ROS release from the mitochondria as 
demonstrated by using the MitoT. The study of detox machinery showed a down-
regulation in sensitive cells after TMZ treatment, consistently with the temporary 
ROS fluctuations. At the same time, an external-mediated increase in intracellular 
ROS level by H2O2 treatment resulted to be able to induce the same mechanisms 
activated by TMZ in sensitive cells after ROS release, determining a responsive 
profile both in sensitive and resistant cells. Of note, here we report that, only the 
concurrent treatment with H2O2 and TMZ induced a completely significant 
responsive profile in resistant cells, confirming the crucial role of ROS, CMA, HIF-1α 
modulation and the drug. The final result of this work is the development of a TMZ-
resistant murine orthotopic model by i.c. injection of CT-2A cells. This model resulted 
to be responsive to RT, as reported by MRI studies. 18F-Fluciclovine tracer was used 
to monitor tumour extent in view of its implementation on the evaluation of response 
to treatment by PET. Finally, preliminary IHC data of untreated and RT-treated mice 
brains have confirmed a down-regulation of ASCT2 expression after RT compared 
to the untreated ones. 
Conclusions: In this thesis work, it has been demonstrated that HIF-1α activity is a 
key player in resistance to TMZ, that CMA has a crucial role in mediating TMZ-
induced cytotoxicity and that the induction of this pathway was due to a transitory 
increase in intracellular ROS level. Moreover, an exogenous increase in ROS levels 
has been able to restore a completely responsive profile in resistant cells opening 
the way for the evaluation of new therapeutic approaches. CT-2A orthotopic murine 
models represent a good opportunity for the in vivo assessment of these new 
treatments, especially using the non-invasive multimodal imaging, strategy 
described herein.   
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1. GLIOMA 
Glioma represents the most frequent Central Nervous System (CNS) 
tumours in adults [1], in fact it accounts for 75 percent of all the primary 
brain cancers. Among gliomas, glioblastoma multiforme (GBM), 
belonging to the high-grade gliomas, is the most diffused one [2]. 
Gliomas are generally categorised in: 
- Diffuse gliomas, defined by a high infiltrative growth within the 
neighbouring parenchyma 
- Non diffused/circumscribed gliomas, as pilocytic 
astrocytoma and ependymomas  
- Rare histological categories [1,2]. 
For what concerns the first category, since diffuse glioma takes origin 
from individual glial or glial precursors cells, it has an infiltrating power 
to occupy brain or spinal cord parenchyma in an uncontrolled manner, 
increasing intracranial pressure, rousing symptoms as headaches, 
emesis, convulsions and brain nerve disfunctions [2,3]. By cellular 
side, these individual cancer cells provoke morphological and 
functional disorders on surrounding neurons and vessels, entrapping 
them and forming with them structures which characterise diffuse 
gliomas. These latter have been classified based on histopathological 
analyses and according to the fifth edition of the World Health 
Organization (WHO) of CNS published in 2016 [1], as follows:  
- Diffuse astrocytomas, whose glioblastoma is the most 
recurrent and aggressive one 
- Oligodendrogliomas 
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- Oligoastrocytomas, with mixed astrocytic and 
oligodendroglial cell populations. 
Another classification that could be taken into account is based on the 
level of mitotic activity, necrosis and vascular proliferation that allows 
assigning a growing malignancy grade (from I to IV) [2]. 
1.1 Genetic Background 
For what concerns the genetic background, a discriminating 
component among diffuse gliomas is represented by the high 
presence of frequent point mutation in isocitrate dehydrogenase 
enzyme, both isoforms 1 and 2, (IDH1 and IDH2) at arginine 132 
(R132) or the analogous residue arginine 172 in IDH2 (R172) in WHO 
grades II and III astrocytomas, oligodendrogliomas, oligoastrocytomas 
and glioblastomas derived by lower grade cancers (defined secondary 
glioblastomas). Strictly related to this IDH mutation, a total 1p/19q co-
deletion has been included as defining gliomas grading [4].  
An intersection between the aforementioned parameters and the 
presence/absence of already described histological features needs to 
be made in order to further compartmentalise diffuse gliomas (which 
are WHO grade II, III and IV, the WHO grade I contains none of the 
aforementioned histologic features) (Figure 1) [5,6] defined as: 
- WHO grade II, as low grade, that can be distinguished in 
astrocytic and oligodendroglial gliomas. As molecular genetic 
signature, this grade presents IDH1/IDH2 mutation and 1p/19q 
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non-codeleted for astrocytomas and 1p/19q-codeleted for 
oligodendrogliomas 
- WHO grade III, defined anaplastic as well and, as for the grade 
II, it is categorised in astrocytic and oligondendroglial gliomas, 
which are different, respectively, for being IDH1/IDH2 mutant, 
1p/19q non-codeleted and IDH1/IDH2 mutant, 1p/19q-
codeleted. Anaplastic glioma is featured by a significant cell 
proliferation, atypical cytological aspect, high vascular 
proliferation, necrosis, and mitotic activity. 
- WHO grade IV, defined also glioblastoma (GBM): this grade 
presents neither mutations in IDH1/IDH2 nor 1p/19q-
codeletion. Moreover, it is characterised by an elevated 
vascular proliferation and necrosis. 
Moreover, in young patients, the histone H3-K27M mutation often 
occurs and presents a poor prognosis; anyhow, in adults grades II and 
III gliomas are mostly IDH-mutant, while grade IV ones often display a 
IDH mutation only when they derive by a lower grade tumours and, for 
this reason, it is defined “secondary glioblastoma”; instead, the defined 
“primary glioblastoma”, that begins directly as a high grade tumour, is 
more recurrent and is properly IDH-wild type, as seen in the Figure 1 
(histone H3-K27M mutation = H; secondary glioblastoma = S, primary 
glioblastoma = P).  
Mainly, some GBM grade IV typical molecular features are widespread 
among lots of diagnosticated grades II and III - IDH-wild type diffuse 
gliomas in adult patients (Figure 1 = red box with exclamation mark). 
Furthermore, some astrocytic cancers which cannot be characterised 
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by tests or whose test results are not satisfying, are classified as “not 
otherwise specified” (NOS) astrocytoma or NOS GBM (Figure 1 = 
hatched bar, number 1), tumours with mixed astrocytic and 
oligodendroglial phenotype and defined NOS 
oligoastrocytoma/anaplastic oligoastrocytoma (Figure 1 = hatched 
bar, number 2); oligodendroglial glioma is specified as 
oligodendroglioma or NOS anaplastic oligodendroglioma in adults and 
as paediatric oligodendroglioma in young patients (Figure 1  = 
hatched bar, number 3) [1]. 
 
 
 
Figure 1: Classification of the diffuse glioma grades according to IDH 
mutation and 1p/19q deletion. 
H = histone H3-K27M mutation; S = secondary glioblastoma; P = primary 
glioblastoma. Exclamation mark = grades II and III-IDH-wildtype diffuse 
gliomas with some glioblastoma molecular aspects; hatched bar, number 1 
= NOS astrocytoma/NOS glioblastoma; hatched bar, number 2 = NOS 
oligoastrocytoma/anaplastic oligoastrocytoma; hatched bar, number 3 = 
oligodendroglioma or NOS anaplastic oligodendroglioma in adults and as 
paediatric oligodendroglioma in young patients (adapted from [1]). 
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1.2 Glioblastoma Multiforme  
Glioblastoma Multiforme (GBM, Astrocytoma IV, WHO) is the most 
aggressive astrocytic brain tumour in adults, it is characterized by a 
high aggressiveness and a median survival which does not exceed 12 
- 15 months [7,8]. As mentioned before, this tumour can arise either 
as primary GBM based on a de novo transformation, or as secondary 
GBM as evolution from already existing low-grade astrocytomas. GBM 
is hard to treat because of its tough microenvironment [9]. 
1.2.1. GBM Cell Heterogeneity 
GBM is characterized by a significant tumour heterogeneity, in which 
several cell populations are involved; in particular, GBM stem cells 
(GSCs) are the most described for their self-renewal and multipotent 
differentiating feature [10]. The GBM tumour microenvironment, 
beyond the presence of malignant astrocytoma cell population and 
GSCs, is made of a high amount of residing and infiltrating immune 
cells (30-40 % of mass, in particular infiltrating macrophages,  stromal 
and vascular endothelial cells and pericytes which all build up niches 
within the GBM itself) [9,11]. All these populations can stay in contact 
within the extracellular matrix (ECM) borders, where non-cellular 
fluidic- and macromolecules-based substrates harbour [12]. Of note, 
niches can be distinguished depending on cell composition, whose 
disposition within the tumour is strictly dependent on GBM modus 
operandi. In other words, it is always clearer that these several tumour 
and non-tumour cell types, as, respectively, highly proliferating and 
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infiltrating astrocytoma cells, GSCs ones, and macrophages, 
microglia, dendritic and lymphocytic cells, cooperate in remodelling 
different tumour components and its behaviour [13]. Focusing on a 
closer perspective, this microenvironment is characterised by the 
tumour core, which is featured by densely aggregated proliferating 
tumour cells, which expands to the more external (peri) necrotic zones, 
perivascular areas circumscribing vessels and (peri) hypoxic areas 
(Figure 2) [11].  
 
Figure 2. GBM tumour microenvironment niches. 
GBM and glioma GSCs are embedded in a heterogeneous tumour 
microenvironment composed of different cell populations and 
compartmentalised in regions defined niches, which regulate metabolic 
needs, immune surveillance, survival, invasion and glioma stem cell 
maintenance. In the angiogenic niche GSCs are positioned very close to the 
abnormal angiogenic vasculature; in the invasive niche tumour cells 
stimulate normal blood vessels to migrate deep within brain parenchyma. In 
the hypoxic niche, a necrotic areas harbour, with surrounding hypoxic 
palisading tumour cells. (Adapted from [9]). 
Moreover, GBM presents a disrupted blood-brain barrier (BBB), 
which is caused by a vascular endothelial growth factor (VEGF) 
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notable expression and that is constituted by a neurovascular unit in 
which endothelial cells, astrocytes and pericytes are involved and all 
together cooperate to strictly modulate molecules and ions passage 
through blood and brain, phenomenon which significantly limits 
transfer of drugs for chemo-treatment [10,14]. VEGF over-expression, 
beyond to cause a BBB disruption, is responsible of abnormal 
vasculature formation, both in morphology and functionality, and also 
hinders GBM-reactive T cells extravasation and this developed 
immune-suppressive environment gives opportunity to GBM tumour to 
escape from host immunosurveillance [12,15]. More in deep, at the 
beginning of glioma proliferation, normal astrocytes are moved away 
from vasculature by astrocytoma cells, interrupting communication 
between astrocytes and vessels, factor which contributes to damage 
blood-brain barrier. Moreover, astrogliosis occurs, phenomenon which 
happens during CNS injuries, that consists of astrocytic cells 
circumscribing GBM cells, starting the proliferation, migration, and in 
the meanwhile several metabolites, growth factors and cytokines 
promoting gliomagenesis are produced [16]. Among all paracrine 
interplays between glioma cells and astrocytes, the connective tissue 
growth factor (CTGF), made by astrocytes, interacts with GSCs 
tyrosine kinase receptor type A (TrkA) and Integrin β1, and this binding 
induces both nuclear factor kappa B (NF-κB) activity and the zinc 
finger E-box binding homeobox 1 (ZEB1), an epithelial–
mesenchymal transition (EMT) transcription factor able to favour 
GBM cells infiltration [17,18]. 
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Of note, a damage to BBB provokes a permeabilization in vessels, 
which in turn causes a fluidic and plasma leaking which spills directly 
to the tumour tissue, originating cerebral oedema and increasing 
interstitial pressure [19]. Another mechanism that originates from this 
damaging is the blood flow braking in obstructed tumour vessels where 
a meaningful decreased oxygen partial pressure (pO2) within tumour 
is observed [20]. This latter phenomenon, known as hypoxia, 
generates a pseudo-palisading necrosis, which in turn recruits 
principally pro-tumoral macrophages, that activate all those pro-
angiogenic and immunosuppressive pathways able to enlarge GBM 
vessels network towards these necrotic areas [21]. Beyond these 
innate immune cells, even endothelial cells, already existing in tumour 
vessels, vasculature progenitors of bone marrow and GSCs are main 
contributors to neo-angiogenesis process [13]. From the molecular 
side, this angiogenic process is driven by the expression of a 
fundamental transcriptional factor: hypoxia-inducible factor-1α (HIF-
1α) (see the paragraph 1.2.6) [22].  
1.2.2 GBM Genetic Characterisation 
Both in primary and recurrent GBM, a pattern of genes results to be 
altered, as follows:  
- p53-dependent DNA damage checkpoint response pathway 
and pRB-dependent cell cycle restriction point pathway [23], 
where in particular, CDKN2A and CDKN2B genes are deleted 
[24,25]. In physiological condition, p53, poorly expressed, is 
modulated by MDM2 and MDM4 (in turn regulated by ARF) 
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through ubiquitination and degradation steps; but, under stress 
conditions as DNA damage, genotoxicity, oncogene activation, 
aberrant growth signals and hypoxia, the p53-MDM2 binding is 
interrupted, triggering to p53 activation. Moreover, according to 
The Cancer Genome Atlas (TCGA, [26]), ARF-MDM2-p53 
pathway is deregulated in 84% of GBM and in more than 94.1% 
of GBM cell lines, while p53 is not regulated in in 22% of GBMs 
[25]. Under physiological conditions, kinases encoded by 
CDKN2A and CDKN2B genes are involved in the CDK4/6 
inhibition through a hyperphosphorylation, causing cell cycle 
brakes at the late G1 phase checkpoint. Their deletion causes 
a cell cycle control missing and an abnormal cell cycle 
progression [27]. 
- Epidermal Growth Factor Receptor (EGFR), that is 
hyperactivated through mutation or amplification. This receptor 
belongs to a larger family of ErbB receptors with tyrosine kinase 
activity and it is involved in a wide range of pathways, both 
ligand-dependent and -independent. In pathologic conditions, 
EGFR overexpression correlates to increased cell survival, 
proliferation, aggressiveness and invasion [28]. 
- TERT promoter, that results to be mutated. It is a guanine-
cytosine rich (GC-rich) promoter which affects TERT 
expression in several frameworks, and it is featured by specific 
recognition sequences binding, for instance, to p53 and the 
aforementioned HIF-1α. When TERT promoter is mutated, its 
expression appears increased and this phenomenon provokes 
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a telomerase activity rescue, which in turn favours malignant 
progression [29]. 
- RTK/Ras/PI3K signalling pathway, which presents mutations 
and also a loss of function of the phosphatase and tensin 
homolog (PTEN) is common. For instance, catalytic and 
regulatory components of this pathway (PIK3CA - PIKC2B and 
PIK3R1, respectively) are mutated and amplified (Table 1) [24]. 
 
 
Table 1: Known and likely pro-tumorigenic genetic alterations in 
primary and recurrent GBM. 
Table includes deletions, amplifications, mutations, and rearrangements 
within 315 genes and 28 introns found in 10 patients’ primary and recurrent 
GBM (adapted from [24]). 
 
RTKs result to be pivotal modulators of all those growth factors-
mediated cascades involved in proliferation, survival and 
metabolism. Of note, GBM cells which surround pseudo-
palisading necrotic regions, express a high level of HIF-1α 
 
12 
 
protein, which in turn contributes to VEGF release, that, as we 
described above, is implicated in neo-angiogenesis. In detail, 
type IV RTKs receptors, as VEGFR 1/2/3 and their co-
receptors, through hypoxia both dependent and independent 
processes, are able to favour GSCs niche proliferation and in 
turn, cancer growth (Figure 3) [30]. 
                              
 
 
Figure 3: The tumour cells in hypoxic conditions induce 
neovascularisation in GBM. 
Herein, tumour cells secrete enhanced levels of VEGF family members, as 
VEGF-A and VEGF-C. RTKs which are specific of endothelial cells, as 
VEGFR-2 and VEGFR-3, through ligand (VEGF-A, VEGF-C) binding, are 
able to stimulate proliferation and migration of endothelial cells. In the peri-
vascular areas, GSCs harbour (adapted from [30]). 
 
1.2.3 Standard Therapy based on Stupp Protocol  
GBM standard therapy follows the Stupp protocol, finely tuned in 2005 
[31]. It is characterized by surgical resection followed by radiotherapy 
(RT) with concomitant Temozolomide (TMZ)-based chemotherapy; 
however, prognosis remains dismal, entailing survival up to maximum 
α 
α 
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two years [7]. In general, GBM has a heterogeneous and infiltrative 
nature and, for this reason, it can acquire a resistant phenotype and 
its response to lots of treatment modalities is not predictable [32]. 
For what concerns radiotherapy, since GBM is characterised by 
elevated aggressiveness and proliferation rate, often radiation 
treatment results inefficient to defeat it [33]. Moreover, from 
biochemical side, GBM cells result to be strongly glycolytic also in 
normoxic conditions, phenomenon called “Warburg effect” [34]. In this 
microenvironment, high levels of superoxide anion (O2-) are mainly 
generated from mitochondria (mt), the high quantity of anion produced 
rapidly undergoes to dismutation to hydrogen peroxide (H2O2), which 
in turn, translocating to the cytosol, mediates the radio-resistance [35]. 
Both O2- and H2O2 constitute some of the Reactive Oxygen Species 
(ROS), which mediate several pathways, but when they overcome a 
threshold concentration within cell microenvironment, may cause the 
so called “oxidative stress”, which may damage cells [36]. In fact, GBM 
cells reply to this potential damage provoked by high levels of ROS, 
augmenting their antioxidant defences, activating a specific detox 
machinery composed of enzymes and molecules, as catalase and 
superoxide dismutase 2 (SOD2) enzymes, glutathione (GSH) 
molecule and GSH-related enzymes (see the paragraph 1.2.8) [37]. 
Ionising radiations cause their cytotoxic effect by inducing ROS 
production, which in turn elicits nucleic acids damage and genomic 
instability. In this way, increased amount of catalase and SOD2 
enzymes improves DNA damage-induced by radiation, contributing to 
the resistance produced by radiation-mediated cell damage. 
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Furthermore, the reduced GSH contribution is pivotal for protecting 
cells from ROS and enhancing radio-resistance. Moreover, lactate 
produced by aerobic glycolysis behaves as an antioxidant, strictly 
relating this molecule to radio-resistance [38]. Moreover, it is now 
always more evident GBM radio-resistance association to 
mitochondria-mediated stress and to consequential over-production of 
Reactive Oxygen Species (ROS) scavengers, that reply to 
radiotherapy shifting cell status to an anti-oxidative one [39]. 
In summary, radio-resistance is composed by a series of orchestrated 
cell replies turned to defend cells from increased ROS levels caused 
by ionizing radiations [40].  
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Temozolomide (TMZ, commercial name Temodal) is an alkylating 
agent, discovered for its antitumor activity for the first time in 1987 and 
approved after in 2005 by Food and Drug Administration (FDA) 
[45,46]; it is able to methylate some DNA bases, specifically Guanine 
in N7 and O6 positions and Adenine in N3 one, during its replication 
(70% for N7-Guanine, 10% for N3-Adenine and 5% for O6-Guanine) 
[7,47]. This molecule is a monofunctional alkylating agent, orally 
INSTRUMENTATION FOR RADIOTHERAPY  
From a biological point of view, radiation represents a waves/stream of 
particle-dependent energy which works for damaging DNA in tumour 
cells, causing cell death. Radiations used for cancer treatment are 
defined “ionising” because they generate ions in cells and 
microenvironment, then “capturing” electrons from atom and molecules, 
and provoking with high likelihood cell damage and growth inhibition [41].  
External beam radiation is the most used technique for RT. Radiations 
are generated by a machine that focalizes the radiation waves to specific 
tissue volumes, for instance the tumour. Usually, the total dose is split in 
smaller doses, called for this reason fractions, which makes the therapy 
lasts for weeks and, in this way, damages to normal tissues are contained 
and radio-responsiveness is maximised [42]. Other radiotherapeutic 
approaches are available such as those related to brachytherapy or 
internal radiation. In this case, a radioactive material is placed directly 
within or close to the tumour area. Through this method, a high dose of 
radiation (compared to external beam radiation) can be focused directly 
on the small tumour area [43].  Finally some radiopharmaceuticals made 
up of a specific carrier labelled with a radioactive atom which decays 
produce a corpuscular emission can be used to provide RT at all the 
potential tumour sites (primary tumour and metastases) since the 
radiopharmaceutical is distributed by blood and localizes in relation to a 
specific molecular feature [44]. 
Although the availability of several RT options new opportunities in this 
scenario are necessary and some improvements attempts are in ongoing 
phase. 
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administered as prodrug: TMZ is hydrolysed at physiologic pH, forming 
the 5-(3-methyltriazol-1-yl)imidazole- 4-carboxamide (MTIC) 
compound, whose hydrolysis to 5-amino-imidazole-4-carboxamide 
(AIC) and methyldiazonium ion reacts with DNA and releases its 
methyl group, causing methyl adducts formation in DNA (Figure 4) 
[47,48].  
 
Figure 4: Temozolomide utilisation for treating GBM. 
A: Mechanism of action of the alkylating agent. B: Formation of methyl 
adducts on DNA bases (adapted from [47]). 
Despite TMZ is used in standard therapy, GBM resistance is an 
important problem, which varies depending on different cell features, 
as genotype, phenotype, mutational state and genetic profile [49].  
A 
B 
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1.2.4 Temozolomide-mediated Autophagy activation 
Temozolomide, beyond to its alkylating action, is able to induce 
autophagy, which is a degradation and recycling process that cell 
adopts when it is exposed to stress conditions. In general, under 
stressors, cell reacts inducing this pathway for surviving, thus recycling 
intracellular proteins and organelles which are damaged, or, 
otherwise, for activating apoptosis (whose the main modulator factors 
are the pro-apoptotic ones BAX and BAD and the anti-apoptotic one, 
BCL-2 [50,51]), because it is no longer able to sustain its vital functions 
[52]. This mechanism has been deeply studied among several works 
in literature, in particular contextualised in pathologic conditions as 
those of tumours: in detail, lots of papers have validated the autophagy 
pro-apoptotic trend in tumour conditions, in particular, TMZ-based 
GBM therapy has the potential to induce autophagic pathway, which 
in turn is followed by G2/M arrest and, consequently, apoptosis , thus 
favouring responsiveness to the treatment [53–55].  
1.2.5 DNA repair mechanisms induced by Temozolomide action 
It is well documented that resistance to TMZ occurs, due to DNA repair 
system activity. Main repair mechanisms are: 
- O6-methylguanine-DNA methyltransferase enzyme 
(MGMT)-mediated direct repair (DR) 
- Mismatch repair (MMR)  
- Base excision repair (BER) [56]. 
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These systems are strictly dependent to the formation of adducts, after 
TMZ administration. The N7 methyl guanine (N7MeG) and N3 methyl 
adenine (N3MA) are more frequent but less harmful compared to the 
less frequent but most dangerous O6 methyl-guanine (O6-MeG). In 
fact, although the high nucleophilic power of the first two adducts, they 
do not cause mismatches and rarely they are powerful to interfere with 
DNA replication with cytotoxic consequences [48]. O6 methyl adduct 
formation is reversed by the MGMT enzyme, a cytoplasmic protein 
which crosses the nucleus when the damage occurs and transfers an 
alkyl surrogate from the guanine oxygen to the Cysteine 145 (C145) 
within its catalytic site, inducing its own degradation through 
proteasome machinery [57]. MGMT has to be continuously expressed 
to ensure its detox activity but its transcription is strictly dependent by 
the methylation status of cysteine-phosphate-guanine (CpG) site in its 
promoter [47]. In fact, the less is the methylation in MGMT promoter 
the higher enzyme activity is guaranteed, thus counteracting TMZ 
effect. On the contrary, a higher promoter methylation percentage 
assures a lower enzyme activity, increasing GBM responsiveness to 
TMZ treatment [7]. For this reason, MGMT methylation promoter 
status has been defined as a TMZ therapy response biomarker in 
clinics (Figure 5A) [58]. Another repair system related to O6- 
methylguanine is the MMR one, which generally removes mismatches 
occurring during DNA synthesis. In specific cases, O6-MeG mispairs 
with thymine are recognized by MMR, which, instead to remove the 
O6-MeG cytotoxic adduct, removes the thymine from the new 
synthetized strand, provoking a mistaken O6-MeG inclusion during 
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replication phase; as consequence, futile cycles occur, which cause 
cell cycle block and apoptosis, mediating TMZ cytotoxic effect [59]. On 
the other hand, a loss of MMR function can be related to TMZ 
resistance, since it does not reply to TMZ-activated mispairing (Figure 
5B) [60,61]. The last cell system repair, the BER one, is activated to 
repair single nucleotide modifications, specifically the N7MeG and 
N3MeA adducts. When this repair mechanism is not functioning in 
GBM cells, TMZ-mediated N7MeG adducts formation result to be 
cytotoxic to cells; furthermore, it has been described that BER 
intermediates able to maintain unpaired gaps are more toxic than the 
original methyl adducts formation. (Figure 5C) [62].  
 
Figure 5: MGMT and other DNA repair mechanisms deal with DNA 
damage produced by the alkylating agent TMZ in cancer cells. 
A: MGMT-mediated direct repair system. B: Mismatch repair mechanism 
(MMR). C: Base-excision repair system (BER) (adapted from [59]).  
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Among the several already described GBM mechanisms of resistance 
to radio-chemotherapy, a  hypoxic microenvironment and HIF-1α 
activity result to be crucial in mediating it. [58,59,63–66].   
1.2.6 Hypoxia and HIF-1α 
As already mentioned, hypoxia, which is a decrease of partial O2 
pressure (pO2) in organs and tissues and which is observed during 
several pathological conditions is a predominant GBM feature [67]. In 
detail, it is mostly resilient within the pseudo-palisading necrotic areas, 
where innate, endothelial, GSCs and bone marrow progenitor cell 
populations are harboured as well [9,22]. Hypoxia is also related to 
GBM resistance to treatment [68]. One of the most important factors 
induced during hypoxia is Hypoxia Inducible Factor-1α (HIF-1α) that 
plays a key role under hypoxic environment. In detail, HIF-1α is 
characterized by an Oxygen-sensor domain, that is highly modulated 
by O2 concentration and it is featured by a short half-life of 5 minutes 
[69]. In normoxia, HIF-1α is continuously degraded, mainly through 
Prolyl-Hydroxylase (PHD) enzymes activity, that are dioxygenase 
which require molecular oxygen, Fe2+ and 2-Oxoglutarate as 
substrates to act, properly hydroxylating P402, P564 and N803 on HIF-
1α. At this point, Von Hippel-Lindau protein (pVHL) is recruited, which 
in turn, retrieves the ubiquitin ligase protein complex consisted in 
elongin B, elongin C, and cullin, which ubiquitinate HIF-1α for 26S 
proteasome degradation. Moreover, among the PHDs, the isoform 2 
has been identified as oxygen sensor which keeps steady state levels 
of HIF-1α under normoxia [70]. Conversely, during hypoxic conditions 
(or in condition in which iron levels are low), this regulatory mechanism 
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is inhibited because PHDs cannot hydroxylate HIF-1α, favouring a 
HIF-1α translocation into the nucleus, where, dimerizing to HIF-1β 
(even known as aryl hydrocarbon receptor nuclear translocator 
ARNT), binds to the cofactor p300/CBP. This new complex binds 
Hypoxia Response Element (HRE) in specific promoter sequences 
and induces genes expression for angiogenesis, glycolytic 
metabolism, mitophagy, stemness, invasiveness and cell cycle 
regulation (Figure 6) [71]. 
 
Figure 6: HIF-1α mechanism of action. 
A: During normoxia, HIF-1α is prolyl-hydroxylated in specific residues, 
reaction which allows its ubiquitination and transfer to proteasome for its 
degradation. B: In hypoxia, HIF-1α is not prolyl-hydroxylated and it is 
translocated into the nucleus where, with HIF-1β, binds HRE sequences on 
DNA and activates expression of genes related on different pathways 
(adapted from [70]). 
 
Among the several pathways activated in hypoxic conditions, HIF-1α 
is implicated also in epithelial-mesenchymal transition (EMT) 
pathway modulation, mediating an increase of the transcription of pro-
A 
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mesenchymal factors, as SLUG [72,73]. Among molecules involved in 
EMT transition process, beyond SLUG, SNAIL and E-cadherin are 
pivotal players. In detail, among the E-cadherin expression 
suppressors, SNAIL and SLUG are the main key players, and both 
belong to the transcriptional activators of SNAIL family and modulate 
the reduced expression of several epithelial markers and the 
augmentation of other different mesenchymal ones. In particular, 
SNAIL transcriptional activity is strictly dependent from its localization 
between nucleus and cytosol. In fact, its phosphorylation triggers to its 
inactivation but TGF-β factor secretion by mesenchymal cells induces 
its translocation into the nucleus via SMAD 2 and 3 proteins. SLUG is 
particularly involved in increasing the high invasion and migration 
power which characterises malignant gliomas [74]. E-cadherin, which 
in gliomas results to be poorly present, belongs to the cadherins family, 
which are transmembrane calcium-dependent cell-adhesion 
molecules, which are key players in tissue building up and 
morphogenesis. In particular, E-cadherin links to the cytosolic β-
catenin, which in turn binds directly to the α-catenin, which binds the 
cadherin system to the actin in the cytoskeleton. An E-cadherin down-
modulation in tumour conditions is related to its high invasiveness and 
metastasis (Figure 7) [75]. 
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Figure 7: EMT in glioma cells. 
Glioma cells lose adhesion molecules and alter their cytoskeleton through a 
reprogramming process. The EMT- reverse process, the Mesenchymal-
Epithelial Transition, is pivotal for the formation of distant or disseminated 
tumour nodules (adapted from [74]). 
 
In GBM HIF-1α covers a very crucial role even in responsiveness to 
TMZ treatment. In particular, HIF-1α activity has been suggested as 
biomarker of TMZ treatment efficacy in U251 TMZ-responsive cells 
[76]. Furthermore, since this pivotal role covered by HIF-1α, this 
transcription factor has been selected as target of cancer therapy in 
clinics, exploiting its inhibitors to target several cancer pathways as 
cell proliferation and invasion, apoptosis, glucose metabolism and 
angiogenesis [77]. In fact, in 2010, a Phase I clinical trial of PX-478 
was completed at two sites in the US after having tested this drug 
against lymphomas and solid tumours [78].  PX-478 (S-2-amino-3-[4-
N, N,-bis(2-chloroethyl)amino] phenyl propionic acid N-oxide 
dihydrochloride) derives from melphalan and is orally bioavailable. A 
suppression of HIF-1α levels in human tumour xenografts and of HIF-
1α target genes, among which vascular endothelial growth factor 
(VEGF) and the glucose transporter-1 (GLUT-1), has been reported. 
Moreover, PX-478 abrogated HIF1α protein levels and its 
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transactivating activity in several cancer cell lines [79]. Of note, it has 
been reported that, among the proteins recognised by one of the three 
authophagy types, the Chaperone-Mediated Autophagy (CMA), HIF-
1α is one of the most important [79]. In fact, in a work of Wen et al, a 
tight relation between  a CMA phosphatase, the Pleckstrin homology 
(PH) domain and leucine-rich repeat protein phosphatase 1 
(PHLPP1), and HIF-1α in colon cancer cells has been found: more 
precisely, hypoxia is able to down-modulate PHLLP1 promoting its 
degradation by proteasome and increasing HIF-1α activity able to 
mediate tumorigenesis in colon cancer cells [87]. 
1.2.7 Autophagy and CMA 
Autophagy, albeit is characterised by three variants which differ from 
sequestration targets, however all of them end with the cargo delivery 
to the lysosomal compartment for its degradation and recycling [80]:  
- Macroautophagy: it is characterised by cargo embedding in 
different double-membrane vesicles until its delivery to the 
lysosome 
- Microautophagy: during this process, lysosomal membrane 
protrusions or invaginations occur for incorporating cargo 
- Chaperone-Mediated Autophagy (CMA): differently to the 
other aforementioned two ones, CMA process does not exploit 
membranous vesicles for embedding cargo, but chaperones 
are pivotal to identify only proteins, as targets, which contain a 
conserved pentapeptide domain (KFERQ, made of Lysine-
Phenylalanine-Glutamate-Arginine-Glutamine).These 
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chaperone-bound proteins are then unfolded and one by one 
translocated across the lysosomal membrane for consequent 
degradation [81]. 
CMA is one of the three main autophagic processes carried out by cell 
in specific conditions of stress, such as lack of nutrients, oxidative 
stress and others [82–84].  CMA consists in the degradation of specific 
proteins carrying the KFERQ-like motif, which are selectively and 
individually delivered to lysosomes by chaperon proteins such as the 
heat shock chaperone 70 kDa (HSC70), with the help of other co-
chaperones. The target proteins are delivered to the lysosomes where 
they bind the lysosome-associated membrane protein type-2A 
(LAMP-2A). This protein works as a receptor on lysosome membrane 
and after polymerisation, introduces the target protein into the 
lysosomal lumen for being degraded, with the contribution of 
lysosomal-HSC70 (lys-HSC70). CMA activity is strictly modulated by 
local LAMP-2A and lysosomal HSC70 amounts [85]. Several works 
have shown HIF-1α degradation in lysosomes through CMA pathway 
[86,87]. Of note, another CMA pivotal component is the Pleckstrin 
homology (PH) domain and leucine-rich repeat protein 
phosphatase 1 (PHLPP1), belonging to phosphatase 2C (PP2C) 
group in the family of S/T phosphatase (Figure 8) [88]. In fact, it binds 
to lysosomal membrane and regulates CMA activity by 
dephosphorylating glial fibrillary acidic protein (GFAP) that in the 
phosphorylated form inhibits CMA [89].  
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Figure 8: Chaperone-mediated autophagy schematic representation. 
CMA, a form of selective autophagy, is involved in degradation of proteins 
containing KFERQ-like motif. Different chaperons, as HSC70, cooperate in 
shuttling target proteins to lysosomes. Herein, after LAMP-2A binding and 
multimerization, the target proteins are unfolded and degraded (adapted 
from [80]). 
 
CMA can be induced by lack of nutrients, and several stressors such 
as oxidative stress. In literature, a Reactive Oxygen species (ROS)-
mediated CMA activation has been reported. Moreover, it has been 
shown that TMZ induces a ROS burst [90]. For this reason, in this 
thesis work, the involvement of oxidative stress in CMA activation is 
analysed. 
1.2.8 Mitochondrial Oxidative Stress  
It has been demonstrated that TMZ-mediated ER stress is responsible 
for the release by mitochondria of ROS and that their release is related 
to TMZ responsiveness [83,91]. Trying to describe a mechanism, a 
high ROS amount and Calcium (Ca2+) overladen provoke 
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mitochondrial permeability transition (MPT) pore opening, which 
triggers mitochondrial membrane potential abrogation and cytochrome 
c and pro-apoptotic factors release, from mitochondrial inner 
membrane space into the cytosol, incrementing even more ROS 
generation and leading to ATP depletion. Mitochondria constitute the 
major ROS producers due to the activity of the respiratory chain. Here, 
molecular oxygen is partially reduced to superoxide anion, the 
hydroxyl radical (OH•) and hydrogen peroxide are generated within 
mitochondrial matrix and intermembrane matrix; in particular, 
superoxide is massively generated by mitochondrial complexes I and 
III through the transfer of a free electron to the O2  [92]. These species, 
being highly reactive, are readily converted to the more stable H2O2 
molecule by manganese superoxide dismutase (MnSOD/SOD2) 
located in the mitochondrial matrix or by the one situated in the 
cytoplasm, the Copper/Zinc SOD (CuZn/SOD1) [93]. Different studies 
have focused on assessing mitochondrial key role in ROS production, 
exploiting several  molecules: among these, MitoTEMPO (MitoT), 
which is a SOD2 mimetic, is able to abrogate mitochondrial ROS 
overproduction and it damages the mitochondrial Oxidative 
Phosphorylation System (OXPHOS) functionality and mitochondrial 
DNA (mtDNA) [94]. Moreover, H2O2 contributes to the activation of 
inflammatory pathways.  It can be reduced by metal ions, as iron or 
copper, forming, through the Fenton reaction, the hydroxyl radical 
OH•, whose formation results highly reactive and dangerous for 
biological macromolecules [95]. Moreover, as shown in Figure 9, other 
hydrogen peroxide detoxification pathways have been described: in 
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detail, the H2O2 can be converted to molecular oxygen and water by 
catalase enzyme or to water and a reduced molecule by means of a 
peroxidase enzyme, as the glutathione peroxidase (GPx) [93,96]. 
 
Figure 9: Reactions of O2- conversion to H2O2, including Fenton 
reaction. 
After O2
- conversion, H2O2, could be converted according to different 
reactions, including the Fenton one (adapted from [97]). 
 
In particular, in GBM cells, since the content of flavoproteins which 
transfer electrons is high, massive amounts of hydrogen peroxide are 
constantly generated as consequence, make H2O2 also a “second 
messenger” [92]. In detail, ROS and, especially hydrogen peroxide, 
have the ability to induce autophagic pathway, which, depending on 
the intracellular status, can be pro-survival or pro-apoptotic. 
Furthermore, only a moderate ROS dose exposure favour autophagy 
activation [95]. Linked to this latter phenomenon, massive ROS 
produced at mitochondria level have the ability to cause a PHD activity 
inhibition, which in turn deactivates proteasome-mediated HIF-1α 
degradation, which, in turn, becomes an autophagic action [98]. 
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In general, beyond the hydrogen peroxide, reactive oxygen species all 
contribute in activating antioxidant enzymes for protecting cells from 
an apoptotic destiny. These detox mechanisms have been therapeutic 
target in different studies [99,100]. At physiological levels, oxidative 
stress and detox system are regulated by a dynamic equilibrium. In 
brain tissue, the most important redox machinery is driven by the 
already described catalase and superoxide dismutase 2 enzymes, 
glutathione (GSH) and GSH-related enzymes:  GSH synthetase 
(GSS), Glutathione Peroxidase (GPx) and GSH Reductase (GR) 
[101]. As discussed in paragraph 1.2.3, GSH protects cells against free 
radicals generated by radiotherapy [102]. In particular, a glutathione 
level increase in GBM cells after TMZ-treatment has been reported, 
showing its strictly relation to TMZ treatment resistance [103]. 
Moreover, intracellular levels of GSH per se and GSH-related 
enzymes are highly associated to TMZ resistance; in fact, resistance, 
together to the redox intracellular balance, is strictly dependent to GSH 
amount and to GSH-associated enzymatic system [99]. In particular, 
GSH synthetase (GSS) enzyme catalyses the condensation of 
gamma‐glutamylcysteine and glycine to form glutathione and 
mutations in the GSS gene provokes the metabolic disorder called 
GSS deficiency in which production of glutathione is prevented [104]. 
The most abundant isoform of Glutathione peroxidase, the GPx1, 
which is located in eukaryotic cytosol and mitochondria, oxidises GSH 
(glutathione reduced form) to GSSG (glutathione oxidised form), 
reducing at the same time Hydrogen peroxide (H2O2) to H2O. In turn, 
GSSG is reduced again to GSH by another key enzyme, glutathione 
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reductase (GR), by exploiting NADPH reducing power. By the way, 
GSH redox machinery is strictly associated to the intracellular redox 
status and energetic metabolism through thiol-disulphide bonds and 
NADPH-NADP system [102]. 
1.2.9 GBM models 
To study GBM, different human and murine cell models are available. 
Commercially available cell models are characterized by different 
genetic feature for MGMT promoter methylation, PTEN, p53 and 
IDH1/2 mutations. These cells possess are useful models for the 
evaluation of molecular mechanisms driving resistance. During the 
experiments described in this thesis work, different glioma cell lines 
have been adopted: U251 and T98 GBM human cell lines, and murine 
CT2A cells (see The Global Bioresource Centre ATCC [105]). 
HUMAN GBM U251 AND T98 CELLS  
These cell lines have been widely used as cell models in several works  
and are already well characterized, because of their easy handling in 
terms of rapid cell growth and, thus, fast performing of assays in order 
to test several types of treatment with high congruency of replication 
for the same treatment [76,106–108]. From genetic side, these two cell 
lines result to be mutated in PTEN and p53 genes, while they are wild 
type for IDH1 gene [109,110]. 
MURINE GBM CT-2A CELLS 
CT-2A cells are a murine GBM cell line already well characterized. 
This cell line derives from a non-metastatic murine glioma [111]. CT-
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2A cell line has been produced from a malignant astrocytoma 
originated through the carcinogen 20-methylcholanthrene implantation 
in the cerebrum of a C57BL/6J mouse. Tumour has been kept via 
serial intracranial transplants prior to cell line isolation. Anyhow, 
beyond their mutation in PTEN gene as U251 and T98, CT-2A present 
no mutations in p53; contrarily to these two human glioblastoma cell 
lines, CT-2A show mutation in IDH1 [112,113]. 
2.1 Glioma in vivo Models 
For studying GBM tumorigenesis and for evaluating new therapies for 
this tumour, cell cultures, beyond their easy handling and reasonable 
costs, cannot allow the multifactorial environment study which in vivo 
deeply affects tumour behaviour. Thus, brain tumour models in 
experimental animals are required, which need not only to reproduce 
as much as possible human GBM features accurately, but also to be 
reproducible per se as well. A glioma mouse model should have the 
following aspects [114]: 
- Cellular heterogeneity and genetic pattern characterising 
glioma patients 
- Needs to be orthotopic  
- Intraparenchymal growing, comprising tumour-stroma 
interactions visualization 
- Non-immunogenic in a host with an undamaged immune 
system 
- High reproducible power with foreseen growing rate 
(accurate estimation of tumour location and dimensions), with 
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faithful imitation of the human glioma therapeutic and immune 
responses. 
Consequently, a glioma mouse model needs to allow these analyses, 
which in vitro result to be limited or not feasible, as listed here below 
[115]: 
- Assessment of all those signals and pathways involved in 
tumorigenesis, tumour maintenance and tumour resistance to 
therapy 
- Faithfulness in reproducing tumour invasion, angiogenesis and 
metastasis 
- Identification of all those local growth factors secreted by the 
tumour per se and the surrounding stroma able to favour tumour 
proliferation and therapy-resistance 
- Self-renewing stem like cells contribution study in cancer 
recurrence. 
Currently, three categories of preclinical glioblastoma models are 
available: xenografts, Genetically Engineered Mouse (GEM) and 
syngeneic murine models [116]. In turn, xenograft models can be 
produced by using cell-lines or patient-derived cells (PDX) [117]. 
Glioblastoma cell line xenografts derive from glioblastoma patients, 
cultured in vitro and implanted in immunodeficient mice (as instance, 
the nude ones); among the commercially available lines, U251 and 
T98 emerge [118–120]. These models, widely used both in vitro and 
in vivo context, are advantageous for their optimal capacity to establish 
and proliferate, to be reproducible for both physiological and 
 
33 
 
pathological conditions [121]. On the other hand, these xenografts do 
not recapitulate clinical aspects of patient tumour, both by genotypic 
and phenotypic sides [122]. PDX, contrarily to the previously described 
model, keeps not only genetic but also histological traits observed in 
primary tumours from which they are obtained: of note, they are not 
influenced by stressors to which instead cell cultures are by, because 
they are bred directly among mice generations. Moreover, they 
originate from injected fresh tumour tissues or from cultured tumour 
spheres implanted into immunodeficient mice and both these 
modalities reflect genetic and phenotypic aspects of original patient 
tumour including multicellularity. Although tumour spheres injection 
presents some difficulties, patient-derived xenografts are pivotal for 
translational approach of glioblastoma [123–126].  
Glioblastoma biology and histology are faithfully recapitulated by 
genetically engineered mouse (GEM) models as well, where usually 
gene expression is modified to favour gene expression/inhibition at a 
precise time/duration or in chosen cells [127]. Also, they can be set up 
by retroviral/adenoviral vectors-mediated transfer of somatic cells 
genetic transfer. These models are helpful to monitor genetic 
modifications involved in tumour initiation and progression, 
consequently to study tumour microenvironment involvement and to 
test therapy efficacy. As for previously described models, even GEM 
present limits, particularly in the lack of perfectly mimicking pathways 
involved in glioblastoma progression and its heterogeneity [128–130]. 
The last category constituted by glioblastoma syngeneic models are 
generated by chemical induction of the tumour (as CT-2A) or by the 
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spontaneous development of a murine glioma [131]. In detail, these 
models retrace glioblastoma histology and biology and, exploiting 
immunocompetent mice, are helpful to study glioblastoma 
immunological and immunotherapy-based features [132]. The still-
open challenge which surround syngeneic models is to deeply test 
their effective ability to mirror human glioblastoma [133]. 
Human GBM in vivo tumour models generated by intracranially or 
subcutaneously implanted glioma cell lines in rodents have been 
massively used for over 40 years and have currently been using [134]. 
As aforementioned, human GBM xenografts implanted in 
immunocompromised mice represents a candidate category among 
mouse models used; for instance, U251 cell model, belongs to this 
category, even if xenogeneic nature negatively affects immune-
mediated anti-tumour strategies assessment. This latter limit is 
overcome by the use of syngeneic glioma models, as, for instance, 
CT-2A murine cell model [135].  
2.2 In vivo Imaging 
In vivo imaging represents a biomedical research field which acts on 
extending monitoring in living small animals to a more tangible view 
[136]. In other words, small animal imaging is a non-invasive and 
repetitive technique applied in living beings which allows biological and 
cellular processes characterisation and evaluation, both at cellular and 
sub-cellular (molecular) levels [137]. Molecular and cellular imaging 
comprises non-invasive imaging techniques as Magnetic Resonance 
Imaging (MRI), Positron Emission Tomography (PET) and the Single 
Photon Emission one (SPECT), Computed Tomography (CT) and 
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Ultrasound (US) imaging, and other procedures initially used for in vitro 
assays, comprising Nuclear Magnetic Resonance (NMR), 
Bioluminescence (BL) and Fluorescence (FL) methods [138]. Some of 
these techniques, as MRI, PET/SPET, CT, US, have been adapted 
and scaled from clinical side to preclinical animal models, going to 
augment their resolution and sensitivity in order to study organisms of 
smaller dimensions; some other in vitro approaches, as BL and FL, 
have been adapted from a cell cultures setting to use them in small 
animals, and sometimes also in humans as well (such as in imaging-
guided surgery or for diagnosis during laparoscopy [139,140]), even if 
its use is still restricted to organs while whole body imaging is not yet 
applicable because of some physical limits [141] . Furthermore, MRI, 
CT and US are defined as anatomical techniques since they allow 
anatomical images of body structures production, while PET and 
SPECT are called functional imaging because they act imaging 
physiological processes and producing functional images. Also BL and 
FL are included among functional imaging techniques, since they allow 
to image gene expression, promoter and transcriptional activity in vivo: 
this analysis result to be very important because all these features 
represent starting points for several deregulated pathways in cancer 
[142]. These approaches have distinct features basing on various 
factors, as follows: 
- spatial and temporal resolution 
- radiation energy and penetration depth, which are functional 
to images production 
- availability or need of contrast agents 
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- threshold detection 
Moreover, they can be distinguished even for providing information 
type, if it is anatomical or functional, as already defined above in Table 
2 [143]. 
 
Table 2: Main non-invasive modalities used for in vivo molecular and 
cellular imaging studies. 
(Adapted from [143]) 
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Thereby, relating to the application, each of these methodologies 
should be used with a distinguished efficiency. Two macro-areas 
among molecular and cellular imaging have been developed:  
- Technologies detection-related area 
- Cell labelling strategies-linked area, including tracers, contrast 
agents and reporter genes/probes [143] 
Moreover, a vastity of molecular imaging approaches have been 
reported, anyway all of them might be categorised in [144]: 
- Direct imaging, where the image is due to the molecular probe 
localization at target level, in a direct manner. The image 
intensity is directly related to the target expression level and its 
binding to the specific molecular probe.  
- Indirect imaging, which is based on reporter gene expression 
imaging. In detail, cells or animals are engineered to express a 
reporter gene which, in turn, codes for a reporter protein, whose 
expression results detectable and quantifiable by imaging, 
immunohistochemistry (IHC) and enzymatic assays without 
difficulties. Reporter expression is activated in relation to the 
occurrence of the molecular event which is studied. After 
reporter protein expression has occurred, a molecular probe, 
which might be a ligand or a substrate, and that is protein-
specific (enzyme/receptor) is exploited in order to image it. 
Imaging reporter genes can code for proteins (enzymes, 
membrane receptors or membrane transporters) both of 
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intracellular type, for instance Luciferase [145], and membrane 
associated (i.e. the dopamine receptor D2R) [146].  
- Functional or tissue microenvironment imaging, even 
defined “metabolic”, “physiological” or “surrogate”. After the 
probe injection, the downstream effect of one or more 
endogenous genes and/or activation/abrogation of molecular 
pathways involved, for instance, in metabolism can be 
monitored, with the aim to define physiologic and pathologic 
tissue conditions. 
Most of the molecular imaging applications exploit the direct imaging 
principle, due to the long-term and well-established probe 
development practice and its wide utilisation in clinical nuclear 
medicine. Anyhow, new specific tracer development for detecting new 
targets is a long and expensive process for biologist, chemists, physics 
and physicians. For bypassing these limitations, the reporter systems 
utilisation has been suggested as a strategy for exploiting as simply as 
possible these non-invasive techniques, at least in small animals. New 
strategies linked to cell imaging have been developed: in detail, 
specific cell populations are labelled in order to monitor some key 
parameters as localisation, survival, distribution, proliferation and their 
function in the organisms. Labelling strategy can be done in two 
different ways: 
- Direct labelling, where a detectable probe links to cell 
membrane or is internalised by isolated cells before they are 
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infused again in the model to be studied. Steps which need to 
be performed are as follows: 
• Sample population harvesting 
• Sample population ex vivo labelling through 
radiolabelled molecule/paramagnetic particles/ 
fluorescent probe 
• Reinfusion 
• Visualisation of labelled population distribution and 
behaviour by means of imaging approach 
Direct strategy advantages reside in the easiness to label cells 
and the availability of clinically approved probes for accomplish 
this process. The big limit is that this protocol does not allow a 
long-term monitoring of cell proliferation in the body since the 
label loss or dilution which in turn is caused by, respectively, 
apoptosis or mitosis (moreover, after cell death the probe might 
be transferred to another cell population, such as 
macrophages, causing an imaging misinterpretation) [141]. 
- Indirect labelling, which provides genetic modification of the 
cell population to study, by inserting reporter genes, whose 
expression is utilised for studying genetically modified cells 
which contain a specific reporter probe. Here some steps are 
provided: 
• Cells harvesting 
• Ex vivo cells transduction with an exogenous reporter 
gene which encodes a reporter product  
• Transduced population reinfusion 
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• Specific tracer administration 
• Visualisation of cell distribution and behaviour in the 
recipient subject by exploiting imaging approach 
This strategy is pivotal for imaging proliferating cells since 
reporter gene is maintained form a cell to the daughter one. By 
using tis approach it could also be possible to non-invasively 
monitor cell activation or differentiation, by using specific 
promoters driving the expression of the reporter gene.  No 
signal dispersion to other cell population will be allowed or 
visualised, only cell viability of the cell population of interest, 
over each monitoring, will be feasible. If this process could be 
advantageous for all the aforementioned aspects, anyway it is 
not so feasible in a clinic scenario. 
 
Figure 10: A schematic representation of the direct and indirect 
imaging strategies. 
A: Direct labelling. B: Indirect labelling. C and D: Imaging of cell progeny 
over time for, respectively, A and B (adapted from [141]). 
A B 
C D 
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For sure, if in vitro approach remains pivotal for monitoring the target 
of interest through molecular and biochemical analyses, the in vivo 
molecular imaging is as much fundamental to evaluate the molecular 
event or the cell population in the whole organism. This latter aspect 
is not permitted by using the in vitro approach alone, because only 
molecular imaging in vivo is able to contextualise the specific in vitro 
data in a holistic approach, made of a sophisticated and dynamic 
network of biological functions and molecular mechanisms occurring 
in the whole body [122,123]. All these listed strategies, particularly in 
an oncological field, allow to carry out a non-invasive monitoring of 
tumour mass over time in individual animals. In this way, the 3R 
principle (Refine, Reduce, Replace) will be faithfully followed, 
because, the animal number for the experimental aim will be limited, 
permitting in the meantime to obtain all the information needed for 
tumour characterization thus increasing statistical power and 
decreasing experimental costs [149]. 
2.2.1 Magnetic Resonance Imaging 
Magnetic Resonance Imaging (MRI) is a non-invasive imaging 
technique which furnishes structural and functional data on organ of 
interest; in particular, it is the reference modality through which 
diagnosis, treatment scheduling and plan and follow-up of neurological 
disease, is performed [150]. This technique uses signal produced by 
hydrogen atoms nuclei (1H), for generating the images. The MRI signal 
is used to measure different variables to be used for image weighing 
(Figure 11) [151]: 
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- T1 longitudinal relaxation/recovery, or spin-lattice interaction, 
due to the energy dissipation of the nuclei to the surrounding 
environment (the lattice), since nuclei have to come back to 
their ground state.  
- T2/T2* transverse relaxation, or spin-spin interaction: it is due 
to the fact that spins lose their phase coherence, without 
dissipating all their energy.  
- Proton density (PD), which is the number of excitable spins in 
a unit volume, which defines the maximum signal which can be 
registered by a tissue. Lowering T1 and T2 parameters is 
possible to ameliorate proton density, for this reason the 
resulting images are named “proton density-weighted” or 
“proton density images”. 
 
 
Figure 11: Sample of MRI images for a normal brain. 
T1: T1-weighted. T2: T2-weighted. PD: proton density (adapted from [152]). 
 
Depending on which of these three parameters are emphasised, MRI 
technique reveals to have a higher potential compared to the CT for 
discriminating soft tissues. Image contrast can be obtained both by 
changing acquisition parameters and sequences, both by 
administering an exogenous contrast medium [153]. Among MR 
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contrast medium agents, one of the most used is a Gadolinium based 
agent able to decrease both T1 and T2 time [154]. More advanced 
acquisition sequences have been developed by simply changing 
acquisition parameters and weighing the images in different variables. 
By using advanced sequences, it is now possible to monitor brain 
function (fMRI), perfusion (DCE), the presence of specific metabolites 
(MRS) and water diffusion (DTI) without the need of exogenous 
contrasts. In particular, diffusion imaging is very important in 
oncological studies since it provides information about tumour 
cellularity and early response to treatment by simply monitoring water 
ability/possibility to diffuse in all the directions. This measure can be 
used for tissue structure reconstruction in terms of cell density, cell 
swelling and fibre presence [155]. MRI technique, exploited from the 
mid-1980’s, has been subjected to several improvements in term of 
resolution, in order to get more defined images of the injured brain 
region. Through this ameliorating process, a gradual transition from 
the first images got with 0.3-0.6 T MR scanner to the currently used 1-
1.5 T or further 3T MRI (and also 7T MRI for small animal imaging), 
which comprises improved imaging quality and diagnostic accuracy 
but even a more rapid acquisition process [156]. The usual MacDonald 
and RANO criteria for glioma management are based on bi-
dimensional tumour measurements made on CT or MRI scans, clinical 
history of patient, and modification in corticosteroid levels after 
treatment, and are utilised for GBM response evaluation. 
Nevertheless, they often provoke mistakable phenomena and wrong 
interpretation, as pseudo-progression or -response because of the 
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blood brain barrier (BBB) and vasculature changes, respectively, in 
integrity and permeability, because of the necrotic processes, post-
operative infarcts and biological effect due to radiotherapy (RT) 
[157,158]. Starting from this consideration, the combination of MRI 
with another imaging technique, such as PET, could improve the 
information obtained by imaging approach [159]. 
2.2.2 Positron Emission Tomography 
Positron Emission Tomography, PET, is a nuclear-based imaging 
technique, which exploits specific radiopharmaceuticals to produce an 
image describing a specific tissue feature depending on the 
radiopharmaceutical used; this technique is able to provide 
quantitative physiological information and can be used in particular for 
tumour evaluation. PET takes advantage of natural biomolecules, the 
radiotracers, which can be labelled with a positron-emitting isotopes, 
such as: 18F, 15O, 11C, 13N (other less frequently used ones are 14O, 
64Cu, 62Cu, 124I, 76Br, 82Rb and 68Ga) [160–162]. These natural 
radioisotopes decay generates a positron emission from their nucleus, 
which by interacting with a neighbouring electron produce a 
phenomenon called “annihilation”, which produces mass particle 
disappearance and the production of two 511 keV photons/γ-rays, 
which are emitted at the same time in an anti-parallel manner, which 
is 180° apart [160]. After radiotracer administration, it distributes to the 
body by blood and it will localize with a higher concentration at the 
target site. Its decay will produce high-energy anti-parallel photons 
acquired by a PET scanner core in the form of a ring-shaped array of 
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photoelectric crystals [163]. These scintillators convert this high 
energy into visible light: this light is captured by photomultiplier tubes, 
which are sensors fitted for converting light into electrons, to decipher 
and convert them in electronics and to translate processing units in 
image. The coincidence through which both photons are detected by 
the tomographic detector within a range of nanoseconds describes the 
line of response in space and the flight direction which contributes to 
define the γ-rays source (physic process defined “electronic 
collimation”). The software reconstructs an image in which the 
positron-emitted radionuclide is shown in a precise localisation and 
concentration within a plane of the scanned organ, easily measuring 
all those coincidence events at all linear and angular positions [164]. 
The most frequently used molecule in the last years for tumour study 
has been 18F-Fluorodeoxyglucose (FDG), which enters the cells 
through GLUT-1 and GLUT-3 transporters, frequently up-regulated in 
cancer, and then it is phosphorylated by hexokinase enzyme in the 
cells, entrapping it. 18F -FDG in relation to the cell glycolytic rate [165]. 
This tracer has been exploited to obtain information about tumour 
grading, extent and prognosis; however, its non-negligible limit is the 
high background in some healthy tissues such as brain (because of 
the glycolytic metabolism pf neurons), liver (again because of glucose 
metabolism), kidneys and bladder (because of tracer elimination) 
[166]. Moreover, even inflammatory cells are able to uptake this tracer 
once they are activators, leading to a misunderstanding in the image 
evaluation. Since these disadvantages, other classes of tracers such 
as amino acidic radiotracers and others have been considered to 
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identify GBM volume delineation, drive biopsy, plan radiotherapeutic 
protocols and evaluate patient follow-up [167]. Generally speaking, the 
identification of a biologically significant biomarker for the identification 
and enhancement of the tumour is needed to identify those tracers 
whose uptake in the lesion can be efficient and specific and can be in 
relation to response to treatment. These biomarkers should be specific 
also for each therapeutic option, since the therapeutics itself could 
interfere with the uptake of the tracer independently from tumour real 
response to the treatment. The accurate choice of both imaging and 
therapeutic strategy in a precision medicine view would improve the 
final results of the treatment [168]. In the effort to monitor GBM tumour 
response to treatment, different tracers have been proposed to 
monitor tumour aminoacidic uptake (FET, MET, FACBC), tumour 
energetic metabolism (DASA), hypoxia (FAZA, MISO) or inflammation 
(TSPO related agents) [168–171]. All these tracers can be used to 
delineate GBM and follow tumour growth and features. Only some of 
them have been proposed for the monitoring of GBM response to 
chemo-radio-immuno- treatments [172]. 
In particular, 18F-Fluciclovine (FACBC) is acquiring a large consensus 
not only in the delineation of tumour volume but also as a strategy for 
the assessment of response to treatment [173]. 
 18F-FLUCICLOVINE RADIOTRACER 
18F-Fluciclovine (FACBC, commercial name Axumin, chemical name 
1r, 3r-1- amino 3-18F-fluorocyclobutane-1-carboxylic acid) is a 
radiotracer which contains an L-leucine amino acid analogue which is 
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radiolabelled with fluorine F-18 [174,175]. FACBC has been approved 
by Food and Drug administration in 2016 (FDA Investigational New 
Drug (IND) 72,437) for detecting prostate cancer [176]: in fact, Oka 
and colleagues have analysed the 18F-Fluciclovine uptake mechanism 
in prostate cancer cell lines by in vitro approach [177]. They have 
shown that FACBC cell internalisation was mediated predominantly by 
Alanine, Serine, Cysteine transporters system, among which Alanine, 
Serine, Cysteine Transporter 2 (ASCT2) and L-Type Amino Acid 
Transporter-1 (LAT-1), which, depending on Sodium (Na+) availability, 
are both overexpressed in lots of cancer types [178–181]. FACBC has 
been tested very recently also in glioma, not only for detecting tumour 
volume, but also for prognostic intent, for the discrimination between 
recurrence and treatment-associated effects and for distinguishing 
low- and high- grade gliomas [182]. Unluckily, although no evidences 
for this radiotracer to show GBM response to treatment have been 
emerged yet, it is a very promising tracer because it is strictly involved, 
in most cases of primary GBM, in an uncontrolled PI3K 
(phosphatidylinositol 3-kinase)/AKT/mTOR (mammalian target of 
rapamycin) signalling pathway, that sustains tumour growth (Figure 
12) [183]. New insights about this radiotracer are necessary to 
ameliorate prognosis of GBM treatment. 
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Figure 12: Internalisation mechanism of 18F-Fluciclovine. 
Schematic representation of 18F-Fluciclovine cellular flux. Internalisation is 
mediated predominantly by system ASC transporters (such as ASCT2) or 
LAT1, depending on Na+ availability (adapted from [180]). 
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AIMS OF THE STUDY 
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The main purposes of the present study have been: 1) to understand 
the molecular mechanisms underlying GBM resistance to TMZ; 2) to 
investigate HIF-1α role in resistance and to assess a new strategy able 
to restore sensitivity to this treatment in previously resistant cells; 3) to 
set up and characterise an orthotopic model of GBM, resistant to TMZ;  
4) to develop a multimodal non-invasive imaging procedure, including 
MRI and 18F-Fluciclovine PET, for monitoring GBM features.  
In detail, in line with the aforementioned purposes, a molecular 
characterisation of the cell lines has been crucial for identifying the 
relation between HIF-1α activity and the responsiveness to TMZ 
treatment. Once demonstrated this relation, since: TMZ, beyond its 
alkylating effect, is able to induce autophagy, chaperone mediated 
autophagy represents one of the main mechanisms through which 
HIF-1α is degraded; since, among CMA activators, ROS cover a 
pivotal role and TMZ is able to produce an ER stress inducing an 
increase or ROS release from the mitochondria, the identification of a 
molecular relation between ROS release, CMA activation and TMZ-
responsiveness in GBM was hypothesised. Moreover, a treatment 
exogenously providing ROS has been positively tested for its ability in 
reverting resistance to TMZ. Results obtained herein will be aimed at 
identifying a new therapeutic approach able to induce a transitory ROS 
increase able to induce CMA, to down-regulate HIF-1α activity and 
recovering sensitiveness to TMZ. To this end, a TMZ resistant GBM 
murine model has been set up together with a strategy for non-invasive 
monitoring of its features, to test new therapeutic approaches also in 
combination with RT.  
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     MATERIALS AND METHODS 
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1. IN VITRO EXPERIMENTS 
1.1 Cell Lines  
Engineered U251-HRE human glioma cells were kindly provided by Dr 
Giovanni Melillo, National Cancer Institute, Frederick (MD). These 
cells express luciferase reporter gene under the control of three copies 
of an HRE sequence, (through stable transfection with pGL2-Tk-HRE 
plasmid), and routinely selected adding G418 antibiotic (disulfate salt 
solution G418, 50 mg/ml, Sigma-Aldrich, St. Louis, MO, US) in culture 
medium. T98 cell lines were engineered for obtaining T98-HRE 
through transient transfection of 3.0 x 104 cells/well with 1 μg of DNA 
(pGL2-Tk-HRE), 24 hours (h) after cell plating.  
Both cell lines have been maintained in Roswell Park Memorial 
Institute (RPMI) 1640 medium, supplemented with 10 % of heat-
inactivated Foetal Bovine Serum (FBS) (EU approved, Euroclone Spa, 
Pero, MI, Italy), Penicillin/Streptomycin antibiotic mix (50 IU/ml, 
Euroclone Spa, Pero, MI, Italy), glutamine (2 mM, Euroclone Spa, 
Pero, MI, Italy).  
Murine glioma cell line CT-2A (kindly provided by Prof. Susan Short, 
St James’s University Hospital, Leeds, UK) has been transiently 
transfected for gaining CT-2A-HRE. Cells engineering has been 
performed through transfection of 5.0 x 104 cells/well, with a 1 μg of 
DNA (pGL2-Tk-HRE) and 2 μl of T-Pro P-Fect (T-Pro Biotechnology, 
Taiwan R.O.C.) for each well in 100 μl of DMEM without serum, 24 h 
after cell plating. 24 h after exogenous DNA incubation, transfection 
successful has been verified. Murine CT-2A cell lines were routinely 
maintained in Dulbecco’s Modified Eagle Medium (DMEM)-High 
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glucose medium (Sigma-Aldrich, St. Louis, MO, US) supplemented 
with 10 % of decomplemented Foetal Bovine Serum (FBS) (EU 
approved, Euroclone Spa, Pero, MI, Italy), Penicillin/Streptomycin 
antibiotic mix (100X, Euroclone Spa, Pero, MI, Italy), glutamine (100X, 
Euroclone Spa, Pero, MI, Italy).  
All these cells have been kept in a humidified atmosphere of 5% CO2 
at 37°C. 
1.2 Drugs and compounds preparation for in vitro treatments 
In vitro treatments have been carried out with the following doses and 
timing: for dose-dependent Temozolomide (TMZ) efficacy 0.1–200 μM 
for 24 hours (h); in all the other experiments, the TMZ dose used was 
100 μM for 24 hours (h); 200μM or 1mM of Hydrogen Peroxide (H2O2) 
for 24h; 25 μM MitoTEMPO (MitoT) for 1h of pre-treatment (all these 
products have been provided by Sigma-Aldrich, St. Louis, MO, US); 
50 μM S-2-amino- 3-[4’-N,N,-bis(chloroethyl)amino]phenyl propionic 
acid N-oxide dihydrochloride (PX-478), the HIF-1α translation inhibitor, 
for 24h (DBA Italia S.R.L, Segrate, MI, Italia). After treatments, 
samples have been analysed for testing cell viability through Trypan 
Blue exclusion assay (0.5 %, Euroclone Spa, Pero, MI, Italy). Glioma 
cells were transfected with 10 nM of HIF-1α or LAMP2A or HSC70 or 
PHLPP1 siRNA or a scrambled negative control (Product No. 
1027280, Qiagen, Hilden, Germany). LAMP-2A, HSC70 and PHLPP1 
siRNA have been realised custom-made by Eurofins company 
(Vimodrone, MI, Italy), while the HIF-1α siRNA has been provided from 
Qiagen (Cat. No. GS3091, Qiagen, Milan, Italy).  Due to the high 
homology (>95%) between the human and murine HIF-1α sequences, 
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the same oligonucleotide used for human cells has been used also for 
the murine ones. All the mentioned siRNAs have been transfected 
utilising T-Pro P-Fect (T-Pro Biotechnology, Taiwan R.O.C.), as 
already described for obtaining T98- or CT-2A-HRE. 
1.3 Cell Viability Assay 
Cell viability was evaluated using the Trypan blue (Sigma-Aldrich, St. 
Louis, MO, US) exclusion test. During the hypoxia experiments, 1.0 x 
104 seeded cells/cm2 were incubated in a hypoxic chamber containing 
a 1% O2 gas mixture. 
1.4 HIF-1α activity evaluation-Luciferase Biochemical assay 
HIF-1α activity evaluation has been performed lysing cell samples with 
lysis reagent (Lysis Reagent 1X, stock 5X, Promega, Madison, WI, 
US). Resulted lysates have been analysed with Luciferase 
Biochemical assay: 20 µl of lysates and 100 µl of Luciferin solution 
(mix made by: Luc Assay buffer 1X, Luciferin 10 mM, DTT 1M, ATP 
200 mM, as described below), and photon emission has been 
measured through luminometer (GloMax-Multi Detection System, 
Promega, Madison, WI, US). Obtained values, expressed in counts, 
have been normalised for protein content, which in turn has been 
gained through Bradford assay (Comassie Plus Protein Assay 
Reagent, Thermo Scientific, Rockford, IL, US) and expressed as 
Relative Luminescence Unit (RLU=counts/mg of proteins). During the 
hypoxia experiments, 1.0 x 104 seeded cells/cm2 were incubated in a 
hypoxic chamber containing a 1% O2 gas mixture. 
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LUC ASSAY BUFFER 1X: 104 mg of (MgCO3)4Mg(OH)2 * 5 H2O 
(Sigma Aldrich St. Louis, MO, US); 150 ml of distilled H2O; 4 ml of 
Tricine 1 M (Life Technologies, Waltham, MA US) , 40 l of EDTA 0.5 
M and 534 l of 1 M Magnesium Sulphate (both from Sigma Aldrich 
St. Louis, MO, US). The solution become clear at pH 7.8, then add 
distilled water to reach a final volume of 200 ml. Sterilization by means 
of a 0.22 m filter and store at 4°C. 
LUCIFERIN SOLUTION: 950 l of Luc assay solution 1X, 550 l of 
luciferin 10 Mm resuspended in distilled water (Promega, Madison, WI, 
US), 33.3 l of DTT 1 M and 2.6 l of ATP 200 mM (both from 
Amersham) for each ml of working solution (prepared at the moment 
of use). 
1.5 Biochemical assay  
The ROS content in each treatment described in section 1.2 has been 
measured utilising ROS-Glo™ H2O2 Assay kit (Promega, Milan, MI, 
Italy). Lysates were analysed through Luciferase Biochemical assay, 
measured using GloMax-Multi Detection System (Promega, Milan, MI, 
Italy). Treatments cytotoxicity has been assayed using CellTox™ 
Green Cytotoxicity Assay kit (Promega, Milan, MI, Italy) and CellTiter-
Glo® Luminescent Cell Viability Assay (Promega, Milan, MI, Italy). 
Glutathione (GSH) detection and quantification has been carried out 
by the commercially available GSH-Glo™ Glutathione Assay 
(Promega, Milan, MI, Italy), after the treatment. Data has been 
expressed as GSH concentration.  
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1.6 HIF-1α Nuclear Quantification 
An ELISA-based kit (TransAM Kit, Vinci-Biochem, Vinci, Italy) was 
used to detect and quantify HIF-1α transcriptional factor activity in 
accordance with the manufacturer’s instructions. The data are 
expressed as the amount of HIF-1α protein in nuclear extract (OD 450 
nm). 
1.7 RNA extraction and real-time PCR 
RNA has been extracted utilising a commercially available Illustra RNA 
spin Mini Isolation Kit (GE Healthcare, Milan, MI, Italy) according to the 
manufacturer’s instructions. Total RNA was reverse-transcribed to 
cDNA through a High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Monza, MB, Italy). The real-time PCRs has been 
accomplished in triplicate for each data point using the Sybr Green 
technique; the oligonucleotides used are shown in Table 3. Changes 
in target mRNA content in relation to the β-ACTIN/β-Actin 
housekeeping gene have been determined using the ΔΔct Method. β-
Actin, Hif-1α and Vegf primer sequences have been used for real-time 
PCR on murine CT-2A samples (Table 3). 
1.8 Wounding assay 
For this test, at the end of the treatment, a wound has been made by 
manually scraping confluent glioma cells monolayer with a p200 
pipette tip. Images at time zero (t=0 h) were captured to record the 
wounds initial area, while the evaluation of the wounded monolayers 
recovery, due to cell migration toward the denuded area, has been 
 
57 
 
performed at 24 h (t=Δh). The wound zone has been quantified by 
Java’s Image J software  [184] and cell migration toward wounds has 
been expressed as wound closure percentage, as follows: 
% wound closure=[(At=0h−At=Δh)/At=0h] × 100%, where, At=0h is the 
wound area measured soon after scratching, while At = Δh is the 
wound area measured 24 h after scratch. 
1.9 Protein analyses 
Samples have been prepared in Novex Bolt LDS sample buﬀer and 
Novex Bolt Reducing Agent and after boiled for 3 min. For protein 
quantification has been performed through Lowry method; proteins 
(10–30 μg) have been loaded in Precast Bolt® Bis-Tris Plus Gels 4–
12% and run for 30 min at 200 V in Novex Bolt 1X MES/SDS Running 
buﬀer. A Trans-Blot® Turbo™ system (BioRad, Hercules, California, 
US) has been used for the transfer to nitrocellulose membrane. 
Membranes have been blocked in Odyssey® Blocking Buﬀer (LICOR, 
Lincoln, Nebraska, US) and incubated with secondary ﬂuorescent 
antibodies (IRDye®). Protein bands have been observed by an 
Odyssey Fc device, model 2800 (LICOR Biosciences LICOR 
Biosciences, Lincoln, Nebraska, USA). Bands intensity quantiﬁcation 
has been done by an Image Studio Lite Ver 5.2 software. Subcellular 
fractions of cells were obtained using Protein Fractionation Kits 
(Thermo ThermoScientific, Waltham, MA US) [185]. Probing with 
samples has been performed using the following antibodies: LAMP2A 
(51-2200 1:1000, Invitrogen, Carlsbad, California, US), HSC70 (MA1-
26078 1:000, Invitrogen, Carlsbad, California, US), GAPDH (sc4772 
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1:1200, Santa Cruz, Santa Cruz, California, US), NDUFB8 (ab110242 
1:1000, Abcam, Cambridge, UK), SDHB (ab14714 1:1000, Abcam, 
Cambridge, UK), UQCRC2 (ab14745 1:1000, Abcam, Cambridge, 
UK), MTCO2 (ab110258 1:1000, Abcam, Cambridge, UK), ATP5A 
(ab14748 1:1000, Abcam, Cambridge, UK), SDHA (459200 1:10000, 
Invitrogen, Carlsbad, California, US), COXIV (A21347 1:2000, 
Invitrogen, Carlsbad, California, US), SOD1 and CATALASE 
(ab179843 1:500, Abcam,  Cambridge, UK), LAMP1 (ab25630 1:900, 
Abcam, Cambridge, UK), ACTIN (A2066 1:200, Sigma-Aldrich, St. 
Louis, MO, US) , GAPDH (sc4772 1:1200, Santa Cruz, Santa Cruz, 
California, US), and α-TUBULIN (3873S 1:800, Cell signalling 
Massachusetts, US) have been used as loading and fractionating 
controls. 
1.10 Biochemical analyses 
Protein extraction has been performed by sonication (50 W for 10 s, 3 
times) after resuspending cell pellets in proper buﬀer (pH 7.2). Lysates 
have been centrifuged at 750g for 10 min and supernatant has been 
recovered. For protein quantiﬁcation Lowry method has been used. A 
Lambda 2 spectrophotometer (Perkin Elmer, Massachusetts, US) has 
been used to determine enzymatic activities. Analyses were 
performed at speciﬁc wave lengths for each enzymatic activity after 
having prepared proper solutions, as previously described with mild 
modifications [185]. Experiments have been performed at 30 °C. A 
Perkin Elmer software has been exploited for performing the analyses. 
Measurements were normalized over the activity level of citrate 
synthase, a stable matrix mitochondrial enzyme; this latter step was 
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performed in order to normalize respiratory chain activity over 
mitochondrial mass. 
Gene Forward Reverse 
BAX ATGGACGGGTCCG
GGGAG 
ATCCAGCCCAACAGCCG
C 
BAD CCCAGAGTTTGAG
CCGAGTG 
CCCATCCCTTCGTCGTCC
T 
BCL-2 GATTGTGGCCTTCT
TTGAG 
CAAACTGAGCAGAGTCTT
C 
PHLPP1 CCTACCTTCTCCAG
TGCACT 
CCAGCAGTTCCAAGTTTC
CT 
LAMP-2A TGCTGGCTACCATG
GGGCTG 
GCAGCTGCCTGTGGAGT
GAGT 
HSC70 ATTGATCTTGGCAC
CACCTA 
GGGTGCAGGAGGTATGC
CTGTGA 
HIF-1α TGATTGCATCTCCA
TCTCCTAC 
GACTCAAAGCGACAGATA
ACACG 
VEGF CGAGGGCCTGGAG
TGTGT 
CGCATAATCTGCATGGTG
ATG 
SNAIL GCGAGCTGCAGGA
CTCTAAT 
CCCGCAATGGTCCACAA
AAC 
SLUG CATGCCTGTCATAC
CACAAC 
GGTGTCAGATGGAGGAG
G 
E-CAD GATCAAGTCAAGC
GTGAGTCG 
AGCCTCT 
CAATGGCGAACAC 
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SOD-2 TTAACGCGCAGATC
ATGCA 
GGTGGCGTTGAGATTGTT
CA 
CATALASE TAAGACTGACCAG
GGCA 
CAAACCTTGGTGAGATCG
AA 
GR AACATCCCAACTGT
GGTCTTCAGC 
TTGGTAACTGCGTGATAC
ATCGGG 
GPX CGCAACGATGTTG
CCTGGAACTTT 
AGGCTCGATGTCAATGGT
CTGGAA 
GSS ATGCTGTGCAGATG
GACTTCAACC 
TGGATGTCAAACAGACGA
GCGGTA 
β-ACTIN TCAAGATCATTGCT
CCTCCTG 
CCAGAGGCGTACAGGGA
TAG 
β-Actin AGGTCATCACTATT
GGCAACGA 
CACTTCATGATGGAATTG
AATGTAGTT 
Hif-1α AGCCCTAGATGGC
TTTGTGA 
TATCGAGGCTGTGTCGA
CTG 
Vegf 
 
GAC CCT GGC TTT 
ACT GCT GTA 
GTG AGG TTT GAT CCG 
CAT GAT 
 
Table 3: Oligonucleotides used for real-time PCR. 
2. IN VIVO EXPERIMENTS 
2.1 Animal studies 
Animal experiments have been performed in compliance with the 
University of Leeds institutional guidelines for the care and use of 
experimental animals. For intra-cerebral injections, an orthotopic 
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murine model was obtained by stereotaxic injection (coordinates: 1 
mm rostral to bregma, 1.5 mm lateral and 3 mm deep) of 2 µl of 
Dulbecco’s Modified Eagle Medium (DMEM)-High glucose medium 
(Sigma-Aldrich, St. Louis, MO, US), containing 1 x 105 CT-2A glioma 
cells into female C57BL/6J mice (also known as: Black 6, B6, B6J, 
C57 Black, Mouse Strain Datasheet: 000664,  The Jackson 
Laboratories [186]) at day 0. For surgery, mice have been placed 
under isofluorane-based gaseous general anaesthesia (Baxter 
International, Deerfield, Illinois, US). Soon after anaesthesia step 
(through Isofluorane), Lubrithal Eye Gel (Dechra Pharmaceuticals 
PLC, Northwich, UK) has been applied on mouse eyes for avoiding 
their drying. Mice have been injected both with 20 µl of Baytril 
antibiotics 0.25% (intramuscular into the back leg; 1:10 of dilution with 
saline) (Bayer, Leverkusen, Germany) and with 10 µL of pain-killer 
Metacam 5% (subcutaneously at the mice back) (Boehringer 
Ingelheim, Ingelheim am Rhein, Germany). Cells were aspirated with 
a 10 μl Hamilton syringe (Hamilton Company, Nevada, US) just 
immediately before the injection. By pointing to a drill (Roboz, 
Gaithersburg, MD, USA)-made hole, Z axis has been fixed to 0 and 
the syringe gently inserted into the brain until reaching the correct 
coordinate (-3 mm depth). Cells were injected with a velocity of 1 
μl/min. Syringe has been left for further 1 minute in the hole before to 
gently remove it, to avoid cell lift in the path of the needle. Hole has 
been closed using Bone wax (Harvard apparatus, St. Laurent, 
Quebec, Canada) and the wound with sterile and self-absorbing glue 
(3M Vetbond tissue adhesive, 3M, St. Paul, MN, USA); soon after, 
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Bacitracin-based antibiotics gel (Polyfax, GlaxoSmithKline, Middlesex, 
UK) has been applied on the wound closure. After surgery, were 
monitored for recovery until complete wakening. Animals have been 
monitored daily for adverse effects, especially for signs of neurological 
symptoms and ill-healthy signs due to chronic intra-cranial pressure, 
as: reduced mobility, hunching, decrease in food intake, 
hypersensitivity upon touching and handling, separation from cage 
mates and a considerable weight loss. In case of these symptoms 
and/or after the end of the experiments, mice have been euthanized 
by perfusion before with saline and soon after with 4% 
paraformaldehyde (PFA) into the heart right ventricle. Brains have 
been collected in 4% PFA and embedded in paraffin for consecutive 
ImmunoHistoChemistry (IHC) analyses.  
2.2 In vivo imaging study design 
In vivo experiments have been carried out on different groups 
(negative controls, controls and RT-treated mice). MRI and PET 
imaging has been used for monitoring tumour growth, effect of RT 
treatment and 18F-Fluciclovine uptake, as described below. 
2.3 MRI analyses 
The MRI scans exploited for confirming the presence of an intra-cranial 
tumour have been performed through a Bartec M7 Machine (1 Tesla, 
Bartec, Bad Mergentheim Germany) located in SBS animal facility. For 
each animal, pictures obtained have been acquired in T2, with 16 
slices in total, 0.8 mm for each slice thickness and 10 minutes-long 
lasting scan as parameters. During acquisitions, mice have been 
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under gaseous inhalation--based general anaesthesia (Baxter 
International, Deerfield, Illinois, US). Tumour ROI volumes have been 
calculated through VivoQuant software [187]. 
MRI imaging was performed on these two groups: 
- Control group: (n=6) (defined in results and graphs as 
“control”), tumour cells were injected as previously described, 
and no RT has been carried out, but only multiple 1T-MRI 
acquisitions in order to monitor the tumour growth and to 
compare it to the RT-treated mice cohorts. Moreover, in an 
experimental point, dynamic and static PET scans have been 
performed for evaluating 18F-Fluciclovine radiotracer 
distribution and uptake in brain tumour. 
- Cohort 1 – RT-treated group 1 (n=6): tumour-bearing mice 
have been treated with RT (three 5Gy-hemibrain radiotherapy 
fractions with SARRP, 15 Gy in total along the entire 
experiment) and the expected tumour mass volume decrease 
has been monitored with several 1T-MRI scans.  
2.4 Radiotherapy 
Radiotherapy has been performed by using the Small Animal 
Radiation Research Platform, SARRP (Xstrahl Life Sciences, 
Camberley, Surrey, UK [188]), according to the following plan: 
- For cohort 1, RT-treated group 1: mice have undergone to 
three 5Gy-hemibrain radiotherapy fractions with Small Animal 
Radiation Research Platform, SARRP, 15 Gy in total along the 
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entire experiment. Each mouse has received the radiotherapy 
in a precise temporal window: days 9,10,11. 
The angle to which radiation beam has been set was from +60° 
to -60°. Treatment duration, for which mice have been 
anaesthetised by isofluorane inhalation, took approximatively 2 
minutes. SARRP machine is implemented with a CT scan, 
which has been useful to better direct radiation beam on brain. 
2.5 Radiotracer availability and PET analyses 
FACBC (18F-Fluciclovine) PET tracer (FDA Investigational New Drug 
(IND) 72,437), which permits in clinics to allows distinguish between 
low and high-grade gliomas (LGGs and HGGs) [182], has been 
provided by Blue Earth Diagnostic Company (Oxford, OX4 4GA, UK) 
through an agreement with University of Leeds (Principal Investigator: 
Prof. Andrew Scarsbrook, Leeds Teaching Hospitals NHS Trust, 
Leeds, UK). Before use, radiotracer has been purified by elution on 
chromatographic column. For each mouse, radiotracer has been 
intravenously injected (tail vein) at the beginning of the 90 minutes-
long-lasting PET dynamic scan or one hour before the 20 minutes 
long-lasting PET static acquisition. At the end of each PET, both 
dynamic and static, an extra 10 minute-Computed Tomography (CT) 
scan has been performed. The PET detection system is made by a 
piece of the Albira Si imaging platform (Bruker, Massachusetts, US): 
this machine contains PET, SPECT (Single Photon Emission 
Tomography) and CT (Computed Tomography) imaging capabilities 
only in one instrument. Mice were anesthetized with isofluorane 
(Baxter International, Deerfield, Illinois, US) and they have been 
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undergone multiparametric MRI scans through a next generation 
Bruker Biospec 7T preclinical MRI machine (Bruker, Massachusetts, 
US) on one day. Anaesthesia times reflect those ones of the 7T MRI 
scans. 
PET imaging was performed on these two groups: 
- Negative Group (n=3), the mice will be injected with only 2 µl 
saline i.c. injection (n=2; sham operated mice) or without any 
i.c. injection (n=1; healthy mouse). This group (defined in 
results and graphs as “non-tumour bearing mice”) has been 
carried out in order to test specific radiotracer localisation at 
tumour injection site. 
- Control group: (n=4) (defined in results and graphs as 
“control”/ ”tumour bearing mice”), tumour cells were injected as 
preciously described, and no RT has been carried out. 
For what concerns regions of interest chosen for PET analyses, the 
following considerations have been done: are the following healthy 
brain region, corresponding to the mid-brain, which is the central back 
of the brain away from tumour injection site, has been used as primary 
control. Liver has been added as the primary metabolic region on 18F-
Fluciclovine. The region of interest was chosen at the bottom lobe of 
the liver for consistency. The tumour, healthy brain and liver regions 
of interest are chosen at the same size for consistency (2 mm diameter 
spheres). The salivary glands and nasal passages are a region of 
interest sized to match the anatomy. 
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2.6 Immunohistochemistry 
Brains collected in 4% PFA at 4 C° temperature have been washed 
twice in Ethanol 70 % and soon after immersed in fresh 4% PFA at 
room temperature for the consecutive paraffine embedding. After this 
passage, embedded brains have been cut in 5 µM slices and soon 
after they have put on glass slides and, in order to monitor tumour 
detection along slices cutting, a fast Haematoxylin and Eosin staining 
has been performed. Immunostaining for ASCT2 (concentration 1/100, 
Abcam, Cambridge, UK) was performed.  
2.7 Statistical analysis 
In vitro experiments have been repeated at least three times and have 
brought to reproducible results. The mice number for each 
experimental group for the in vivo analyses have been defined in the 
paragraphs above. Data are shown as the mean values ± SD of 
independent experiments and were statistically analysed utilising a t 
test or one- or two-way analysis of variance, followed by Dunnett’s or 
Bonferroni’s multiple comparison and Prism 4 software (GraphPad 
Software Inc., San Diego, CA, US).  
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RESULTS 
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Figure 13: Dose–response viability of responsive and resistant cells 
after TMZ treatment under normoxic conditions. 
1. IN VITRO RESULTS 
1.1 GBM cell profiling of responsiveness to TMZ treatment 
In vitro characterisation of TMZ responsiveness was assessed in two 
glioma cell lines (U251 and T98) that have different percentage in 
MGMT promoter methylation (65 % and 40%, respectively). U251 and 
T98 GBM cell lines have been treated with TMZ for 24 hours. In U251 
MGMT-highly methylated cells, the viability was significantly reduced 
after treatment with TMZ, while in the T98 MGMT-low methylated cells, 
TMZ did not influence cell viability (Figure 13).  
 
 
 
 
 
 
 
Cell viability has been assessed through a Trypan blue exclusion test and 
expressed as the percentage of viable cells after 24, 48, or 72 h of treatment 
at increasing doses of TMZ under normoxic conditions. A: U251 cells. B: T98 
cells. **p < 0.01 TMZ-treated cells vs untreated cells. Mean values ± SD. 
TMZ responsiveness was also investigated in hypoxic condition, 
showing that U251-responsive cells became more resistant to TMZ 
compared to their trend in normoxia: indeed, in hypoxia five times 
higher dose of the drug is needed to induce a significant cytotoxicity 
even in methylated cells (Figure 14). 
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Figure 14: Dose–response viability of responsive and resistant cells 
after TMZ treatment under normoxic and hypoxic conditions. 
Cell viability has been assessed through a Trypan blue exclusion test and 
expressed as the percentage of viable cells after 24, 48, or 72 h of treatment 
at increasing doses of TMZ under normoxic and hypoxic (grey-coloured) 
conditions in A: U251 cells and B: T98 cells. **p < 0.01 TMZ-treated cells vs 
untreated cells. Mean values ± SD. 
As shown in Figure 14, since hypoxia is able to modulate TMZ 
treatment, we have focused on assessing the contribution of the main 
factor driving cell response to hypoxia, HIF-1α, in responsiveness to 
TMZ treatment, selecting one TMZ dose (100 µM), which will be used 
for all the following results reported. Firstly, HIF-1α levels in the 
nucleus have been monitored and, only in responsive cells, both in 
normoxia and hypoxia, TMZ treatment produced a reduction of the 
nuclear HIF-1α amount (Figure 15A and B). Moreover, sensitivity to 
TMZ was also related to a modulation of HIF-1α activity. In fact, in both 
normoxic and hypoxic conditions, while in sensitive cells a reduction in 
the activity of this transcription factor after treatment was also 
detected, in resistant cells TMZ treatment failed in modulating HIF-1α 
activity (Figure 15C). 
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Figure 15: Nuclear HIF-1α localisation of responsive and resistant cells 
after TMZ treatment, both in normoxic and hypoxic conditions. 
ELISA-based HIF-1α nuclear quantification after TMZ treatment under 
normoxic and hypoxic conditions has been carried out in A: U251 cells and 
B: T98 cells. The data are expressed as absorbance at 450 nm. *p < 0.05 vs 
control under normoxic/hypoxic conditions. C: Luminescent assay applied to 
evaluate HIF-1α activity, both in untreated cells and after treatment with 100 
µM TMZ, both in normoxia and hypoxia. Data were expressed as Relative 
Luminescence Units (RLU) obtained by luciferase counts normalised to the 
amount of proteins quantified by Bradford assay. *p < 0.05, **p < 0.01, ***p 
< 0.001 treated vs control under normoxic/hypoxic conditions. Mean values 
± SD of three independent experiments. 
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The effect of TMZ treatment on cell viability was also confirmed by the 
analysis of the gene expression profile for some apoptotic genes (BCL-
2, BAX and BAD). Indeed, real-time PCR showed that TMZ treatment 
was able to significantly induce pro-apoptotic genes such as BAX and 
BAD with the down-regulation of the expression of the anti-apoptotic 
BCL-2 gene. This expression pattern has been defined a “sensitive-
like” expression profile.  
In hypoxic condition, since hypoxia itself dramatically changed HIF-1α 
expression and activity as well as BCL-2 expression profile, TMZ 
treatment reduced only partially the amount of nuclear HIF-1α 
producing a partial resistance as confirmed by the lower induction of 
proapoptotic genes and the lack of negative modulation of BCL-2 
expression compared to normoxic untreated controls. 
In T98 cells, the TMZ-resistance was also confirmed in hypoxic 
condition. For what concerns their apoptotic expression pattern, in 
resistant cells, both hypoxia and TMZ induced the up-regulation of 
BCL-2 anti-apoptotic gene that we associated with a “resistant-like 
expression pattern” (Figure 16). 
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Figure 16: Gene expression of the apoptosis-related genes (BAX, BAD, 
BCL-2) in TMZ-responsive and -resistant cells treated with TMZ under 
both normoxic and hypoxic conditions. 
The induction of anti-apoptotic (BCL-2) and pro-apoptotic genes (BAX and 
BAD) was analysed by means of real-time PCR. Data were normalised to β-
actin, and the ΔΔCt values were expressed as FOI of the ratio between 
treated and control cells. *p < 0.05, **p < 0.01, ***p < 0.001 treated vs control 
cells. #p < 0.05, ##p < 0.01, ###p < 0.001 vs TMZ-treated cells. Mean values 
± SD of three independent experiments. 
1.2 HIF-1α degradation and chaperone-mediated autophagy 
involvement in GBM responsiveness 
TMZ treatment, as already described (see the INTRODUCTION-1.2.4-
1.2.6), is able to induce autophagy and within the different molecular 
pathways involved in HIF-1α degradation, Chaperone-mediated 
Autophagy plays an important role [86].  
Taking into account that TMZ induces autophagy, that HIF-1α is a 
Chaperone-mediated Autophagy (CMA) target and its activity 
decreased in relation to TMZ responsiveness, a connection among 
HIF-1α activity modulation, TMZ-responsiveness and CMA has been 
hypothesised. Firstly, a gene expression profile for the main CMA-
related genes, LAMP-2A, PHLLP1 and HSC70, and for HIF-1α has 
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been performed in U251-sensitive and T98-resistant cells after 
treatment with TMZ. Gene expression analysis showed that treatment 
was able to increase LAMP-2A, HSC70 and PHLPP1 expression, and 
concomitantly, to reduce the HIF-1α transcript in TMZ-sensitive cells, 
while in resistant cells, alkylating agent produced an opposite 
response. 
 
Figure 17: Gene expression of the CMA-related genes (LAMP-2A, 
PHLLP1 and HSC70) and of HIF-1α in TMZ-responsive and -resistant 
cells treated with TMZ. 
Gene expression analysis for CMA-related genes (LAMP-2A, HSC70, 
PHLPP1) and HIF-1α analysed by means of real-time PCR in U251 and T98 
cells after treatment with 100 µM TMZ. Data were normalised to β-actin, and 
the ΔΔCt values were expressed as FOI of the ratio between treated and 
control cells. *p < 0.05, **p < 0.01, ***p < 0.001 treated vs control cells. #p < 
0.05, ##p < 0.01, ###p < 0.001 vs TMZ-treated cells. Mean values ± SD of 
three independent experiments. 
Furthermore, in order to better define protein levels of two of the CMA 
key-players, LAMP-2A and HSC70, after alkylating agent treatment, a 
Western Blot analysis in U251-sensitive cells and T98-resistant ones, 
both in presence and absence of TMZ, has been performed. A 
statistically significant increase has been detected in both CMA 
proteins level in U251 cells after TMZ treatment compared to their 
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respective controls, whereas in T98 cells, after TMZ treatment, LAMP-
2A and HSC70 amounts did not show any change in  their level that 
resulted to be reduced compared to basal levels, although in a no 
statistically significant manner. Thus, these data support crucial CMA 
engagement in responsiveness to TMZ treatment (Figure 18). 
 
Figure 18: LAMP2A and HSC70 quantification. 
Western blot analysis of LAMP2A and HSC70 in protein lysates from 
untreated (-) and TMZ-treated (+) U251 and T98 cell lines. Protein signals 
were normalised to actin levels. Histograms show mean values of protein 
arbitrary units evaluated in independent experiments. Errors bars indicate 
standard deviation. * p < 0.05 treated versus untreated. Mean values ± SD 
of three independent experiments. 
In order to assess LAMP-2A and HSC70 intracellular localisation, a 
cell fractionation has been performed in U251 and T98 cells under 
control condition and after TMZ treatment. Results showed an 
increase in LAMP2A and HSC70 proteins in the lysosomal fraction in 
U251 cells after TMZ treatment. This increase was not detected in T98 
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resistant cells after TMZ treatment. At the same time, we studied also 
GAPDH levels to monitor CMA activity since it is a CMA substrate [89]. 
Cytosolic GAPDH level was decreased only in sensitive cells after 
treatment with TMZ and increase in the lysosomal fraction in the same 
condition thus confirming the selective involvement of CMA only in 
U251 cells (Figure 19). 
 
Figure 19: Essential CMA-related gene involvement in TMZ response. 
A: Western blot analysis of LAMP2A, HSC70 and GAPDH protein levels in 
subcellular fractions obtained from untreated (-) and TMZ-treated (+) U251 
and T98 cell lines. B: Protein signals were normalised to respective fraction 
markers: TUBULIN (cytosol) and LAMP1 (lysosomes). Histograms show the 
distribution of target proteins in the fractions after 24 hours of TMZ treatment 
compared to untreated control levels. **p < 0.01 treated versus untreated 
control levels. Mean values ± SD of three independent experiments. 
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To further analyse CMA role in responsiveness to TMZ, we silenced 
different CMA-related genes (LAMP-2A, HSC70 AND PHLPP1) both 
in sensitive and resistant cells and silenced cells were treated with 
TMZ. In U251-responsive cells, CMA-related genes silencing 
produced the acquisition of a TMZ-resistant behaviour (Figure 20). 
In detail, blocking CMA activity through the silencing of the CMA-
related genes, cytotoxicity normally due to TMZ-treatment was 
abrogated, as shown in a missing reduction in viability (Figure 20A), 
as well as in HIF-1α activity (Figure 20B). In T98-resistant cells, TMZ-
responsiveness and HIF-1α activity was not changed under the same 
experimental conditions (Figure 20C and D).  
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Figure 20: Viability analysis in U251 (A) and T98 (C) and Luminescent 
Assay on U251 (B) and T98 (D) after LAMP-2A, PHLPP1 or Hsc70 
silencing ± 100 µM TMZ treatment. 
A and C have been assessed by means of Trypan blue exclusion test. Data 
were expressed as percentage of viable cells. **p < 0.01 treated vs control 
cells. ###p < 0.001 vs TMZ-treated cells. B and D have been performed 
through Luminescent assay applied to evaluate HIF-1α activity, both in 
untreated cells and after 24h treatment with 100 µM TMZ. Data were 
expressed as Relative Luminescence Units (RLU) obtained by luciferase 
counts normalised to the amount of proteins quantified by Bradford assay. 
**p < 0.01 vs control cells. ###p < 0.001 vs TMZ-treated cells. Mean values 
± SD of three independent experiments. 
Also, gene expression analyses of CMA-related genes, of HIF-1α and 
one of its primary target genes, VEGF, under the same conditions 
confirmed the acquisition of TMZ-resistance in TMZ-treated U251 cells 
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after LAMP-2A, HSC70 or PHLPP1 silencing. In particular, it seems 
that PHLPP1 silencing, more than the LAMP-2A one, has increased 
the HIF-1α and VEGF expression in these cells, showing again the 
CMA engagement in responsiveness to TMZ treatment (Figure 21A, 
B). On the other hand, silencing of LAMP-2A, HSC70 and PHLPP1 
genes did not change responsiveness to TMZ in T98 and these cells 
maintained their resistant-like behaviour even for HIF-1α/VEGF gene 
expression (Figure 21 C, D).   
 
Figure 21: Gene expression of the CMA-related genes (LAMP-2A, 
PHLLP1 and HSC70) and of HIF-1α and VEGF after silencing of CMA-
related genes ± TMZ in U251 and T98 cells. 
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Gene expression analysis for CMA-related genes (LAMP-2A, HSC70, 
PHLPP1) and HIF-1α and VEGF were analysed by means of real-time PCR 
in U251 and T98 cells. Data were normalised to β-actin, and the ΔΔCt values 
were expressed as FOI of the ratio between treated and control cells. *p < 
0.05, **p < 0.01, ***p < 0.001 treated vs control cells. #p < 0.05, ##p < 0.01, 
###p < 0.001 vs TMZ-treated cells. Mean values ± SD of three independent 
experiments. 
EMT-linked (SNAIL, SLUG and E-CAD) gene expression profile 
investigation reported no changes among these genes in LAMP-2A, 
HSC70 and PHLPP1-silenced U251 cells; the situation was different 
after TMZ treatment, in fact a SNAIL and SLUG expression increased 
and E-CAD mRNA amount decreased confirming a mesenchymal-like 
expression profile induction, which generally is obtained in TMZ-
resistant cells (Figure 22A). Contrarily, T98-resistant cells did not 
produce any alteration in EMT genes modulation neither after LAMP-
2A, HSC70 and PHLPP1 silencing per se, nor after TMZ treatment 
(Figure 22B). 
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Figure 22: Gene expression of the EMT-related genes (SLUG, SNAIL 
and E-CAD) after silencing of CMA-related genes ± TMZ in U251 (A) and 
T98 (B) cells. 
Gene expression analysis for EMT-related genes (SLUG, SNAIL and E-CAD) 
were analysed by means of real-time PCR in U251 and T98 cells. Data were 
normalised to β-actin, and the ΔΔCt values were expressed as FOI of the 
ratio between treated and control cells. *p < 0.05, **p < 0.01, ***p < 0.001 
treated vs control cells. #p < 0.05, ##p < 0.01, ###p < 0.001 vs TMZ-treated 
cells. Mean values ± SD of three independent experiments. 
The same silencing and TMZ treatment scheduling has been 
performed for HIF-1α, both in sensitive and resistant cell lines. Viability 
assay in U251 cell line has been shown that the silencing of HIF-1α 
alone did not reduce cell viability and, after TMZ treatment, no 
silencing mediated-additive effects have been observed (Figure 23A). 
From what concerns HIF-1α activity evaluation, it was reduced by TMZ 
only in sensitive cells, and further decreased after HIF-1α silencing 
(Figure 23B). On the other hand, HIF-1α silencing has significantly 
decremented cell viability after TMZ treatment in the resistant T98 cells 
(Figure 23A). This result was confirmed from biochemical luciferase 
assay, where TMZ treatment alone was not able, as expected, to 
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decrease HIF-1α activity in T98 cells and the result was overturned 
only in simultaneous presence of TMZ and HIF-1α silencing, reverting 
the previous resistant-like behaviour in a sensitive-like one (Figure 
23B). The molecular consequences of HIF-1α silencing have been 
assessed by monitoring the expression of the apoptosis-related genes 
(BCL-2, BAX, BAD). Moreover, TMZ treatment activated an inverse 
modulation of pro- and anti-apoptotic genes in U251 and T98 cells. 
However, HIF-1α silencing in U251-responsive cells has not induced 
any further modulation of apoptosis-related genes beyond that 
obtained after TMZ treatment, but HIF-1α silencing in resistant cells 
restored a “sensitive-like pattern” in apoptosis-related gene 
expression, with the upregulation of BAX and BAD expression, and a 
reduction in BCL-2 transcript levels (Figure 23C). 
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Figure 23: HIF-1α silencing induces a responsive-profile in TMZ-
resistant cells. 
A: Viability of U251 and T98 was assessed by means of Trypan blue 
exclusion test and expressed as the percentage of viable cells after HIF-1α 
silencing. *p < 0.05, **p < 0.01, ***p < 0.001 vs control cells. B: HIF-1α 
dependent luciferase activity in U251 and T98 was analysed in cell lysates 
and expressed as the percentage variation in relative luminescence units 
(RLUs). *p < 0.05, **p < 0.01, ***p < 0.001 vs control cells. C: After silencing, 
the cells were treated with TMZ and the induction of BCL-2, BAX and BAD 
and genes was analysed by means of real-time PCR. The data were 
normalised to β-actin, and the ΔΔCt values were expressed as FOI of the 
ratio between treated and control cells. Results of sensitive and resistant 
cells were presented as FOI mean values ± SD. *p < 0.05, **p < 0.01, ***p < 
0.001 treated vs control cells. Mean values ± SD of three independent 
experiments. 
With the aim to assess whether HIF-1α pharmacological inhibition 
could produce the same consequences of HIF-1α gene silencing, T98 
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cells have been treated with a specific HIF-1α inhibitor, PX-478. Cell 
viability data showed a statistically significant reduction of cell viability, 
compared to the untreated controls, both after PX-478 treatment per 
se and after combined treatment with TMZ, recovering cell sensitivity 
to TMZ (Figure 24A). This trend was in line with HIF-1α activity 
reduction measured with the biochemical assay (Figure 24B). 
 
Figure 24: HIF-1α pharmacological inhibition, in particular after TMZ 
treatment, affects T98-resistant cells viability and HIF-1α activity. 
A: Cell viability of resistant cells was assessed by means of Trypan blue 
exclusion test and expressed as the percentage of viable cells after PX ± 
TMZ. *p < 0.05 vs control cells. B: HIF-1α dependent luciferase activity was 
analysed in cell lysates and expressed as Relative Luminescence Units 
(RLU) obtained by luciferase counts normalised to the amount of proteins 
quantified by Bradford assay. *p < 0.05 vs control cells. Mean values ± SD 
of three independent experiments. 
1.3 ROS are key player in TMZ-response contribution  
Recent studies show that TMZ is able to induce an increase in 
cytoplasmic ROS levels that is important for the induction of cell 
toxicity [84]. At the same time, other papers report that a transitory 
increase in ROS levels can induce CMA activity [83,103,189]. 
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Endogenous ROS levels were measured in TMZ-responsive U251 and 
TMZ-resistant T98 cell lines both in control condition and after 
treatment with TMZ. These cells exhibited a different intracellular ROS 
basal level, which in the resistant ones is 8-fold higher compared to 
the sensitive ones. After 24h-TMZ treatment, in responsive cells, ROS 
amount resulted statistically increased, while in T98 ones TMZ 
treatment was not able to further increase cytoplasmic ROS (Figure 
25A). The experiment has been replicated by treating cells with the 
selective mitochondrial (mt) ROS scavenger MitoTEMPO (MitoT), 
which has been able to reduce ROS levels in both cell lines, confirming 
their mitochondrial origin. However, ROS levels remained still higher 
in TMZ-resistant cells (Figure 25B and C). 
 
Figure 25: Mitochondrial ROS involvement in TMZ-responsiveness. 
A: Luminescent assay applied to measure H2O2 levels in cell culture medium 
of U251 and T98 cells in untreated cells and after 24h treatment with 100 µM 
TMZ. Data were expressed as Relative Luminescence Units (RLU) obtained 
by luciferase counts normalised to the amount of proteins quantified by 
Bradford assay. **p < 0.01 vs control cells. B and C: ROS levels measured 
in U251 and T98 cells after 1h of treatment with MitoT 25µM ±TMZ for 24h. 
Data were expressed as RLU. #p < 0.05, ##p < 0.01 vs TMZ-treated cells. 
Mean values ± SD of three independent experiments. 
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Once confirmed that intracellular ROS-related to TMZ treatment 
originate from mitochondria, U251 and T98 cells were treated with 
MitoT to analyse their role in response to treatment. In U251 cells, 
MitoT was able to reduce cell sensitivity to the TMZ treatment, 
observed both as regards cell viability and toxicity tests as well as in 
relation to HIF-1α activity which did non decrease (Figure 26A, B and 
C). Moreover, TMZ-induced pro-apoptotic gene expression pattern 
observed in U251 cells was abrogated through MitoT treatment, 
conferring a resistant -like apoptosis-related gene expression profile 
to these cells, as shown in Figure 26D. 
 
Figure 26: Crucial role of mitochondrial ROS in TMZ-responsiveness in 
U251 cells. 
A: Viability of U251 analysed through Trypan blue exclusion test and 
expressed as the percentage of viable cells after treatment with 100 µM TMZ 
± 25 µM MitoT. **p < 0.01 vs control cells; #p < 0.05, ##p < 0.01 vs TMZ-
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treated cells. B: Cell toxicity in U251 assessed by Cell Tox Green normalised 
on Cell Titer Glo and expressed as percentage compared to control cells. **p 
< 0.01, ***p < 0.001 vs control cells. C: Biochemical assay for HIF-1α activity 
in U251-responsive cell line. Data were expressed as RLU, obtained 
normalising luciferase counts to the amount of proteins quantified by 
Bradford assay. **p < 0.01 vs control cells. D. Gene expression analysis for 
BAX, BAD and BCL-2 analysed through Real-time PCR in U251 cells after 
treatment with 100 µM TMZ ± 25 µM MitoT. Data were normalised to β-actin, 
and the ΔΔCt values were expressed as FOI of the ratio between treated and 
control cells and then as the ratio BAX/BCL-2 and BAD/BCL-2. *p < 0.05, **p 
< 0.01 treated vs. control cells. #p < 0.05 vs TMZ-treated cells. Mean values 
± SD of three independent experiments. 
A different result was observed in T98 cells, where after MitoT 
treatment no changes neither in cell viability nor in cell toxicity were 
observed even after treatment with TMZ. Similar results were obtained 
not only in HIF-1α activity evaluation but even in apoptosis-related 
gene expression profile analysis: in fact, BAX/BCL-2 and BAD/BCL-2 
ratio after TMZ treatment maintained a “resistant-like profile”, also in 
combination with the SOD-mimetic (Figure 27). 
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Figure 27: Crucial role of mitochondrial ROS in TMZ-responsiveness in 
T98 cells. 
A: Viability of T98 analysed through Trypan blue exclusion test and 
expressed as the percentage of viable cells after treatment with 100 µM TMZ 
± 25 µM MitoT. B: Cell toxicity in T98 assessed by Cell Tox Green normalized 
on Cell Titer Glo and expressed as percentage compared to control cells. C: 
Biochemical assay for HIF-1α activity in T98-resistant cell line. Data were 
expressed as RLU, obtained normalising luciferase counts to the amount of 
proteins quantified by Bradford assay. *p < 0.05 vs control cells. D. Gene 
expression analysis for BAX, BAD and BCL-2 analysed through Real-time 
PCR in T98 cells after treatment with 100 µM TMZ ± 25 µM MitoT. Data were 
normalised to β-actin, and the ΔΔCt values were expressed as FOI of the 
ratio between treated and control cells and then as the ratio BAX/BCL-2 and 
BAD/BCL-2. Mean values ± SD of three independent experiments. 
In line with these data, we investigated the role of mtROS in regulating 
CMA activity. Specifically, CMA-related (LAMP2A, PHLPP1, HSC70) 
and hypoxia-linked (HIF-1α and VEGF) gene expression was analysed 
by real-time PCR in U251 and T98 cells. In U251 cells, LAMP-2A, 
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HSC70 AND PHLPP1 genes, as expected, were up-regulated after 
TMZ-treatment, whereas the co-treatment with MitoT reverted the 
gene expression profile (Figure 28A). This resistant-like expression 
profile can be observed also for HIF-1α and VEGF gene expression, 
which increased as in resistant cells (Figure 28B). 
 
Figure 28: Gene expression analysis for CMA-related genes (LAMP-2A, 
HSC70, PHLPP1) and HIF-1α and VEGF in U251 cells. 
These genes have been analysed by means of real-time PCR in U251 after 
treatment with 100 µM TMZ ± 25 µM MitoT. Data were normalised to β-actin, 
and the ΔΔCt values were expressed as FOI of the ratio between treated and 
control cells. *p < 0.05, **p < 0.01, ***p < 0.001 treated vs control cells. #p < 
0.05, ##p < 0.01, ###p < 0.001 vs TMZ-treated cells. Mean values ± SD of 
three independent experiments.   
In resistant T98 cells, MitoT by itself induced a statistically significant 
reduction in LAMP-2A expression and in combination with TMZ a 
further significant reduction in the expression of all CMA-related genes 
was observed (Figure 29A). Moreover, in T98 cells MitoT treatment 
did not exert any influence on HIF-1α mRNA modulation both as single 
treatment and in combination with TMZ (Figure 29B).  
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Figure 29: Gene expression analysis for CMA-related genes (LAMP-2A, 
HSC70, PHLPP1) and HIF-1α and VEGF in T98 cells. 
These genes have been analysed by means of real-time PCR in T98 after 
treatment with 100 µM TMZ ± 25 µM MitoT. Data were normalised to β-actin, 
and the ΔΔCt values were expressed as FOI of the ratio between treated and 
control cells. *p < 0.05, **p < 0.01 treated vs control cells. Mean values ± SD 
of three independent experiments. 
Since HIF-1α is also involved in the regulation of EMT, we performed 
a scratch test in both cell lines, to observe how differently the treatment 
might influence wound healing. EMT gene expression was analysed 
as well. In U251 cells TMZ treatment inhibited the closure of the 
scratch even at 24h, while MitoT treatment was able to prevent TMZ-
mediated cell toxicity provoking the complete scratch closure in 24 
hours (Figure 30A). Results were supported by EMT gene expression 
analyses (SNAIL, SLUG AND E-CAD). In fact, while TMZ induced an 
epithelial-like expression profile in U251 cells with high expression of 
E-CAD and low expression of SNAIL and SLUG genes, the 
combination with MitoT produced an opposite mesenchymal-like 
pattern with an increase in SNAIL and SLUG expression and a 
reduction of E-CAD mRNA level (Figure 30B). 
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Figure 30: EMT involvement in TMZ response in U251 cells. 
A: Scratch test performed after treatments in U251 cells. Wound closure 
percentage compared to controls was analysed with ImageJ software. **p < 
0.01 treated vs control cells. ##p < 0.01 vs TMZ-treated cells. B: Gene 
expression analysis for EMT-related genes (SLUG, SNAIL, E-CADHERINE) 
analysed by means of real-time PCR in U251. Data were normalised and 
expressed as mentioned above. **p < 0.01, ***p < 0.001 treated vs control 
cells. ##p < 0.01, ###p < 0.001 vs TMZ-treated cells. Mean values ± SD of 
three independent experiments. 
In T98 cells, MitoT treatment did not change neither wound healing 
kinetic and EMT-related gene expression, both as single treatment 
and in combination with TMZ (Figure 31). 
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Figure 31: EMT involvement in TMZ response in T98 cells. 
A: Scratch test performed after treatments in U251 cells. Wound closure 
percentage compared to controls was analysed with ImageJ software. **p < 
0.01 treated vs control cells. ##p < 0.01 vs TMZ-treated cells. B: Gene 
expression analysis for EMT-related genes (SLUG, SNAIL, E-CADHERINE) 
analysed by means of real-time PCR in U251. Data were normalised and 
expressed as mentioned above. **p < 0.01; ***p < 0.001 treated vs control 
cells. ##p < 0.01, ###p < 0.001 vs TMZ-treated cells. Mean values ± SD of 
three independent experiments.  
1.4 Redox-balance deregulation association to GBM TMZ-
responsiveness 
For a better investigation of the processes contributing in ROS 
increase after TMZ treatment in responsive cells, mitochondrial and 
cytosolic detox mechanisms were evaluated. Due to the dependence 
of the ROS production and, consequently, of the redox-homeostasis 
by the respiratory chain, the mitochondrial respiratory chain 
complexes activities (I, II, I+II and IV) have been measured both in 
U251 and T98 cells, both basally and after 24 h of TMZ-treatment. 
Complexes I, III and IV basal activities resulted to be significantly 
higher in resistant cells compared to the sensitive ones; this 
discrimination was kept even after alkylating agent treatment (Figure 
31A). No variations have been detectable in citrate synthase amounts, 
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showing no changes in mitochondrial global content (data not shown). 
T98 treated with TMZ did not show any appreciable reduction in 
complex activities (Figure 31B). 
 
 
Figure 32: Deregulation of redox-homeostasis. 
Spectrophotometric analysis of mitochondrial respiratory chain complex 
activities measured before and after 24 hours of treatment with TMZ in U251 
(A) and (B) T98 cells. Values are expressed as mean values of complex I, II, 
I+III and IV normalised to citrate synthase activities (pmol/min/mg of 
proteins). Mean values ± SD of three independent experiments. 
For testing whether these differences among mitochondrial complexes 
are due to altered stability in mitochondrial respiratory chain 
complexes, SDS-PAGE analysis of the key-player OXPHOS subunits 
has been performed in the same samples used for the biochemical 
approach. No consistent differences between U251 and T98 cell lines 
have been appreciated neither in basal conditions nor after TMZ 
treatment (Figure 32); these findings support the idea that augmented 
OXPHOS activities and TMZ reduction  observed in T98 cells might 
derive from deregulated OXPHOS homeostasis and/or altered ROS 
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management while steady state levels of mitochondrial proteins are 
conserved. 
 
Figure 33: Western Blot analyses of OXPHOS subunits. 
A: Western Blot image of representative subunits of the mitochondrial 
respiratory chain analysed before and after 24 hours of TMZ treatment. B: 
Quantification of the aforementioned subunits in U251 cells. C: 
Quantification of these subunits in T98 cells. Values are expressed as mean 
values of protein content (arbitrary units) normalised to the signal of Porin 
(VDAC). Mean values ± SD of three independent experiments. 
Since the importance of ROS level modulation within the cells and its 
dependence from the cellular redox system, the expression of the main 
enzymes involved in detoxification from ROS were analysed by both 
real-time PCR and activity assays. In U251 cell line, the expression of 
glutathione peroxidase, synthetase and reductase (GPX, GSS and 
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GR), superoxide dismutase 2 (SOD2) and CATALASE genes resulted 
to be down-modulated after TMZ treatment. On the other hand, in T98 
TMZ-resistant cells, an up-regulation in the expression of CATALASE, 
glutathione synthetase and reductase genes has been observed 
(Figure 34A). Intracellular GSH levels were monitored in U251 and 
T98 cells and it has been shown that T98 cells possessed a higher 
GSH level compared to U251 at control condition. However, while in 
U251 cells TMZ treatment decreased GSH level compared to controls, 
GSH level did not change after treatment in T98 cells (Figure 34B). 
 
Figure 34: Investigation on ROS level modulation within the cells and 
its dependence from the cellular redox system. 
A: Gene expression profile for Detox enzymes (SOD-2, CATALASE, GR, 
GPX and GSS) after treatment with 100 µM TMZ in U251 and T98 cells. Data 
were normalised to β-actin, and the ΔΔCt values were expressed as FOI of 
the ratio between treated and control cells. *p < 0.05, **p < 0.01 vs control 
cells.  B: Glutathione concentration assessed after TMZ treatment in both 
cells by means of a commercially available kit. Data were expressed as 
glutathione concentration (μM). *p < 0.05 treated vs control cells. Mean 
values ± SD of three independent experiments. 
In order to define the redox-homeostasis role in TMZ responsiveness, 
the protein levels of the key players of the detox machinery have been 
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assessed: in detail, we showed decreased CATALASE and SOD-1 
residual levels after TMZ treatment only in U251 responsive cells, 
differently from T98 resistant ones, where SOD-1 resulted to be 
statistically augmented after 48 hours of TMZ-treatment. Herein, SOD 
cytosolic isoform protein, SOD-1, has been studied in relation to ROS 
presence into the cytosol (Figure 35). 
 
Figure 35: Analyses of the protein levels of the key players of the detox 
machinery in responsiveness to TMZ. 
A: Western blot analysis of CATALASE and SOD in protein lysates from 
untreated (-) and TMZ-treated (+) U251 and T98 cell lines at 24 hours of 
treatment. B: Quantification of the aforementioned proteins. Protein signals 
were normalised to actin levels. * p<0.05, ** p<0.01 treated vs control. Mean 
values ± SD of three independent experiments.  
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1.5 Induced-oxidative stress helps to sensitise T98 cells in TMZ-
treatment 
Since it was well described the involvement of a transitory increase in 
ROS levels in inducing CMA activity, a treatment with H2O2 has been 
used to evaluate its ability in inducing CMA activity, especially in T98 
cells, also in combination with TMZ. Firstly, a H2O2 dose response has 
been performed for testing which H2O2 doses showed the most 
significant results both in responsive and resistant cell lines, however, 
for better summarising this work, the dose response data are not 
shown. Cell viability has been carried out for monitoring both TMZ-
responsive and -resistant cell lines after treatment with a “mild” and a 
“high” H2O2 dose also in combination with TMZ. Both the treatments 
have been previously described in literature [190–193]. 
In detail, “mild” H2O2 oxidative stress (200 µM) did not affect cell 
viability compared to controls and did not increase cell cytotoxicity in 
combination with TMZ in U251 cells; on the other hand, the use of the 
“high” H2O2 oxidative stress caused a reduction in cell viability 
comparable to what obtained also in combination with TMZ (Figure 
36A). Results were confirmed by the apoptotic gene expression assay 
(Figure 36B). For what concerns T98 resistant cells, mild H2O2 (200 
µM) oxidative stress, produced no effect in cell viability; while after the 
high H2O2 (1 mM) dose, a decrement in cell viability was observed, 
both in single and in TMZ-combined treatment (Figure 36C). 
Moreover, apoptosis-related gene expression analysis showed that 
only the higher H2O2 dose in combination with TMZ had the potential 
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to change gene expression towards a “pro-apoptotic” phenotype 
(Figure 36D).  
 
Figure 36: Induced oxidative stress and its role in overcoming 
resistance to TMZ. 
A and B: Viability analysis and gene expression profile for apoptotic-related 
genes (BAX, BAD and BCL-2) in U251 cells. C and D: The same analyses 
performed in U251 have been done in T98 cells. Viability was assessed 
through Trypan blue exclusion test after treatment with 200µM or 1mM H202 
± 100 µM TMZ. Data of viability were expressed as percentage of viable cells; 
**p < 0.01, ***p < 0.001 treated vs control cells. All data of gene expression 
were normalised to β-actin, and the ΔΔCt values were expressed as FOI of 
the ratio between treated and control cells. *p < 0.05, **p < 0.01, ***p < 0.001 
treated vs control cells. 
As regards CMA, “mild” H2O2 treatment triggered an increment in 
CMA-linked genes expression, except for HSC70 with a consequent 
significant expression rise in HIF-1α and VEGF mRNA levels 
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compared to controls. Differently, oxidative stress induced by 1 mM 
H2O2 was able not only to significantly activate LAMP-2A and HSC70 
expression, but even to significantly decrease the HIF-1α and the 
VEGF ones, while no modulation in PHLPP1 expression was 
appreciated. Its expression was up-regulated only after concurrent 
treatment with “high” H2O2 and TMZ (Figure 37A and B). In T98 cells, 
only the “high” H2O2 dose induced a “sensitive-like” expression pattern 
in CMA-related genes, that was completed only in combination with 
TMZ, with a significant decrease both in HIF-1α and VEGF expression 
(Figure 37C and D). 
 
Figure 37: Gene expression profile for CMA-related genes (LAMP2A, 
HSC70, PHLPP1), and for HIF-1α and VEGF. 
A and B: Gene expression profile of the previously mentioned genes in 
U251. C and D: Gene expression profile of the previously mentioned genes 
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in T98 cell. A-D all performed after treatment with 200µM or 1mM H202 ± 100 
µM TMZ. All data of gene expression were normalised to β-actin, and the 
ΔΔCt values were expressed as FOI of the ratio between treated and control 
cells. *p < 0.05, **p < 0.01, ***p < 0.001 treated vs control cells. #p < 0.05, 
##p < 0.01, ###p < 0.001 vs TMZ-treated cells. Mean values ± SD of three 
independent experiments. 
Finally, as regards EMT evaluation, in U251 cells “mild” H2O2-
mediated oxidative stress did not induce any therapeutic effect as 
single treatment, while, even as a single treatment, the “high” H2O2 
dose induced an epithelial-like expression pattern similar to that 
obtained with TMZ single treatment and a concomitant delay in wound 
closure. Combination with TMZ did not provide any further effect 
different from those already obtained with the only TMZ treatment 
(Figure 38A, B). In T98 cells on the other hand, only the “high” H2O2 
dose favoured a delay in the scratch closure and a concomitant EMT 
expression profile close to an epithelial-like one. Once again, only in 
combination with TMZ, “high” H2O2 dose produced a complete 
epithelial-like expression pattern with down-regulation of SNAIL and 
SLUG expression and an increase in E-CADERINE mRNA (Figure 
38B and C).  
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Figure 38: EMT role in induced oxidative stress related to TMZ 
treatment. 
A and B: Scratch test and gene expression for EMT-related genes (SLUG, 
SNAIL, E-CADHERINE) performed after treatments in U251. C and D: The 
same experimental procedures have been adopted also for T98 cells. Wound 
closure percentage compared to control was analysed with ImageJ software.  
**p < 0.01 treated vs control cells. ##p < 0.01 vs TMZ-treated cells. Data of 
gene expression were normalised and expressed as mentioned above. *p < 
0.05, **p < 0.01, ***p < 0.001 treated vs control cells. #p < 0.05, ##p < 0.01 
vs TMZ-treated cells. 
1.6 CT-2A characterization 
Murine GBM CT-2A cell line has been characterised in an in vitro 
experimental setting to characterise their responsiveness to TMZ.  
MGMT methylation promoter analysis reported a 28% of promoter 
methylation. TMZ treatment, as shown in Figure 39, was not able to 
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induce a reduction in cell viability and Hif-1α expression and activity 
(related to one of its primary target, Vegf), demonstrating that these 
GBM murine cells are characterised by TMZ resistance similarly to T98 
cells. Moreover, in CT-2A cells, as already demonstrated for T98 
resistant cells, HIF-1α silencing allowed the recovery of cell sensitivity 
to TMZ (Figure 39).  
 
Figure 39: CT-2A cell line characterisation in relation to responsiveness 
to TMZ. 
A: Viability analysis in CT-2A after Hif-1α silencing ± 100 µM TMZ treatment. 
Viability test has been assessed by means of Trypan blue exclusion test. 
Data were expressed as percentage of viable cells. ***p < 0.001 treated vs 
control cells. ###p < 0.001 vs TMZ-treated cells. B: Gene expression 
analysis for Hif-1α and Vegf were analysed by means of real-time PCR in 
CT-2A cells. Data were normalised to β-actin, and the ΔΔCt values were 
expressed as FOI of the ratio between treated and control cells. *p < 0.05, 
**p < 0.01 treated vs control cells. #p < 0.05, ##p < 0.01. Mean values ± SD 
of three independent experiments. 
Finally, according to the H2O2-mediated-oxidative stress data reported 
in T98 cells (see the paragraph 1.5), CT-2A treated with the “mild” 
H2O2 dose were not affected by the treatment, both for their viability 
and in HIF-1α activity. On the other hand, the use of the high H2O2 
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concentration triggered a significant decrease not only in Hif-1α and 
Vegf expression (Figure 39B), but also in cell viability and in HIF-1α 
activity, especially in combination with TMZ (Figure 40A, B). As 
regards wound healing in CT-2A cells, as already described for T98 
cells, only 1mM H2O2 treatment in combination with TMZ induced a 
significant wound closure delay (Figure 40C). 
 
Figure 40: Induced oxidative stress and its role in overcoming 
resistance to TMZ in CT-2A murine cells. 
A: Viability assay has been assessed by means of Trypan blue exclusion 
test. Data were expressed as percentage of viable cells. *p < 0.05, ***p < 
0.001 treated vs control cells. #p < 0.05, ###p < 0.001 vs TMZ-treated cells. 
B: HIF-1α activity evaluation has been performed through Luminescent 
assay applied to evaluate HIF-1α activity, both in untreated cells and after 
24h H2O2 treatment ± 100 µM TMZ (A). Data were expressed as Relative 
Luminescence Units (RLU) obtained by luciferase counts normalised to the 
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amount of proteins quantified by Bradford assay. *p <0.05, ***p < 0.001 vs 
control cells. #p < 0.05 vs TMZ-treated cells. C: Scratch test performed after 
treatments in CT-2A. Wound closure percentage compared to control was 
analysed with ImageJ software. ##p < 0.01 vs TMZ-treated cells. Mean 
values ± SD of three independent experiments. 
2. IN VIVO RESULTS 
2.1 In vivo non-invasive GBM model characterization by MRI 
CT-2A cells were used to implement a murine model of GBM resistant 
to TMZ, since it has been already reported that T98 cells cannot be 
used to produce ortothopic models [194–196].  
C57Bl/6J mice received an intracranial (i.c.) stereotaxical injection with 
CT-2A murine cells, then tumour growth was monitored by using MRI, 
9 and 15 days after cell injection, as shown in Figure 41. 
 
 
Figure 41: Timeline of the MRI acquisitions. 
The procedures, shown in red contoured squares, are described following 
the days. D0 represents the i.c. injection day.  Two consecutive MRI scans 
were performed at days 9 and 15, the first one to check if the tumour was 
grown after surgery and the second one to monitor the tumour growing.    
Data analysis from MRI acquisitions showed an average tumour 
volume of 1.27 mm3 ± 0.93 at day 9 post-injection which increased 
 
104 
 
after further six days to an average volume of 13.62 mm3 ± 3.03, 
(Figure 42A, B, C). MRI images have been performed in T2 (T2-
weighted images, T2W), where brighter regions represent tumour 
sites. T2W-MRI data quantitation showed about a 25% increase in T2 
values in tumours compared to unaffected contralateral regions 
(Figure 42B and C). In fact, the bright signal in the T2W data 
represents a combination of tumour and oedema. DTI representative 
data showed the tumour disrupting normal white matter pathways with 
a visible ring of high FA that points to the tumour margin (Figure 42D). 
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Figure 42: MRIs analyses on orthotopic mice models set up by i.c. 
injection of CT-2A murine cells. 
T2W-MRI have been carried out on days 9 and 15. A: T2-MRI at day 9 after 
i.c. injection. B: T2-MRI at day 15 after i.c. injection. C: Quantification of 
tumour growth monitored by MRI. T2W-MRI data showed about a 25% 
increase in T2 values in tumours compared to unaffected contralateral 
regions. ***p < 0.001 tumour volumes at day 15 vs tumour volume at day 9. 
In figure D: representative DTI acquisition showing the tumour disrupting 
normal white matter pathways with a visible ring of high FA that points to the 
tumour margin. Tumour ROI volumes have been calculated through 
VivoQuant software.  
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2.2 CT-2A murine cells represent a good cellular model for the in vivo 
analyses for GBM responsiveness to radiation therapy 
In order to assess the efficacy of an external radiation treatment, 
15Gy-hemibrain radiation therapy (RT) has been fractionated into 
three sessions at days 9,10,11. GBM bearing mice, both controls 
(tumour-bearing mice without RT) and treated were monitored by MRI 
for tumour volume assessment. RT induced a significant reduction in 
tumour volume as clearly shown in Figure 43A. Moreover, the 
treatment induced also an increase in the OS of all the treated mice 
(Figure 43B). 
 
Figure 43: Evaluation of RT efficacy. 
A: Tumour volume monitored by MRI in controls (tumour-bearing mice) and 
RT-treated mice. *p < 0.05 RT-treated vs controls. Mean values ± SD. B: 
Kaplan-Meier survival curves showing OS of controls versus treated tumour 
bearing mice. 
In summary, these data have shown that murine glioma CT-2A cells 
are responsive to radiotherapy and can be used as a model of TMZ-
resistant, RT-sensitive GBM in vivo. 
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2.3 Validation of 18F-Fluciclovine as a tracer for GBM monitoring 
by PET 
The same orthotopic models already described for MRI studies were 
used to set up a PET acquisition with 18F-Fluciclovine to evaluate this 
tracer for GBM volume monitoring and potentially response to 
treatment. To this end, a first evaluation of tracer uptake during time 
has been carried out by performing a dynamic 90 minutes-PET 
acquisition 16 days after cell stereotaxic injection. Radiotracer has 
been injected i.v. (intravenously) when PET acquisition started. As 
shown in Figure 44, activity measurement was carried out in different 
Regions of Interest (ROIs): Healthy brain (blue), Tumour (green), 
Nasal passages (yellow), Salivary glands (purple), Liver (the region of 
interest is chosen at the bottom lobe of the liver for consistency). 
Image has been scaled between 0 and 3 SUV.  
Time activity curves have shown radionuclide uptake in different ROIs 
during the 90 minutes acquisition (Figure 44A). A high uptake has 
been observed in salivary glands and nasal passages, however 
tumour uptake increased progressively overcoming that of other 
organs from 60 minutes after injection. These curves have been 
helpful to set up the following static acquisition in order to maximise 
tumour to background ratio (Figure 44B).  
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Figure 44: Dynamic PET. 
A: 90 minutes-PET on a representative tumour bearing mouse. 18F-
Fluciclovine PET has been done 16 days after cell stereotaxical injection. 
Radiotracer has been injected i.v. when PET acquisition started. Activity 
measurement was carried out in different Regions of Interest (ROIs): Healthy 
brain (blue), Tumour (green), Nasal passages (yellow), Salivary glands 
(purple), Liver (the region of interest is chosen at the bottom lobe of the liver 
for consistency). B: Time activity curves showing radionuclide uptake in 
different ROIs. Tumour uptake (green line) was higher than that of other 
organs from 60 minutes after injection (green square). Data are expressed 
in SUV. 
Static PET acquisitions started 60 minutes after 18F-fluciclovine 
injection in both negative control and tumour bearing mice. SUV has 
been measured in different ROIs and averages of ratios between each 
tissue SUV Max and the respective liver SUV Max, have been reported 
(Figure 45). Maximum intensity projection images has shown the 
ability to identify tumour volume in tumour bearing mice by 18F-
Fluciclovine uptake while no specific uptake in the brain has not been 
found in negative control animals. A high uptake of the tracer was 
detected in the liver, as expected because of tracer metabolism 
(Figure 45A and C). SUV Max quantification and normalization on 
liver SUV Max showed that tumours are characterized by a specific 
higher uptake of this tracer compared with all the other organs (Figure 
SUV 
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45B). The evaluation of tumour-to-brain ratio demonstrated the 
possibility to discriminate the tumour from normal brain, being 
statistically different (Figure 45D). 
 
Figure 45: Static PET scans performed on non-tumour and tumour 
bearing mice. 
Acquisition started 60 minutes after 18F-Fluciclovine injection. Acquisition 
included Static PET (20 minutes) and a CT (10 minutes). Images are 
expressed in Maximum Intensity Projection (MIP). A: MIP for non-tumour 
bearing mouse. B: MIP for tumour bearing mouse. C: Maximum 
Standardized Uptake Value (SUV Max) in different ROIs for tumour bearing 
mice. Each SUV max has been normalised with the respective liver SUV 
Max. D: Ratios between the SUV Max measured at the injection site both in 
control and in tumour bearing mice and the respective SUV Max measured 
in normal brain. *p < 0.05 tumour bearing mice vs non-tumour bearing mice. 
2.3 Preliminary results about the IHC 
From preliminary results of IHC of untreated vs RT-treated mice 
brains, the amino acid transporter ASCT-2 staining seemed to reveal, 
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at tumour bulk area, a higher cellularity levels in untreated mice brains 
compared to those ones RT-treated. Representative IHC data of 
untreated and treated mice brains are shown in Figure 46. 
 
Figure 46: Representative IHC data on ASCT-2 staining of untreated and 
treated mice brains. 
A: IHC staining for ASCT-2 in representative untreated mouse brain. B: IHC 
staining for ASCT-2 in representative RT-treated mouse brain.  
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DISCUSSION 
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Up to date, TMZ is the reference drug used in GBM patients in 
combination with radiotherapy [31]. The development of resistance is 
still a challenge since there are no equally valid alternative therapies 
[8]. In this thesis work, different GBM cell lines have been 
characterised in order to elucidate molecular mechanisms related to 
their responsiveness or resistance to TMZ. Main aim, in fact, has been 
the definition of a mechanism which was useful to modulate a switch 
of resistant cells toward a “sensitive-like” GBM phenotype. O6-
MethylGuanine Methyl-Transferase promoter methylation has been 
considered as the key prognostic factor in GBM patients handling [58], 
but, not necessarily this situation has been always confirmed: indeed, 
in different cases, MGMT-methylated cells resulted to be resistant to 
TMZ-treatment and, instead, low MGMT methylated ones resulted to 
be sensitive to the alkylating agent [197,198]. Thus, there is the need 
of identifying new predictive biomarkers, to foresee GBM 
responsiveness to TMZ with higher reliability. A different TMZ-
response between two human GBM cell lines, the U251 cells and the 
T98 ones, respectively TMZ-sensitive and TMZ-resistant, has been 
observed, both in normoxia and hypoxia. The higher resistance to TMZ 
in hypoxic conditions, led us to focus on the role of HIF-1α, the main 
character conducing cell response to hypoxia. Results showed that 
HIF-1α expression and activity were in relation to cell responsiveness 
to TMZ: in fact,  we confirmed the early reduction of both its expression 
and activity specifically observed only in sensitive cells, as  already 
reported in literature [76,199]. Through apoptosis-related gene 
expression profile evaluation, after TMZ treatment, in normoxia a 
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reciprocal expression pattern in TMZ-responsive and -resistant ones 
has been observed; on the other hand, hypoxia seemed to produce an 
anti-apoptotic profile also in sensitive cells. This pattern is similar to 
the one observed in T98 cells after TMZ treatment both in normoxia 
and in hypoxia. This data allowed to propose not only HIF-1α as an 
early biomarker of tumour response to TMZ treatment [199], but it also 
elicited a new interest about HIF-1α related mechanisms potentially 
accountable for GBM resistance to TMZ.  
Since it is well known that temozolomide is capable of inducing 
autophagy and HIF-1α is a target protein for a specific kind of 
autophagy called Chaperone mediated autophagy (CMA) [86,87], we 
have wondered if CMA itself might be the key-mechanism which 
regulates responsiveness to TMZ. This molecular mechanism has 
three different steps, whose impairment might result in an alteration of 
the activity. The first potential alteration could involve the activity and 
availability of the carrier proteins which bind target proteins exposing 
KFERQ-like motif, as HSC70 and other related proteins, vehiculating 
them to the lysosomal compartment. The second control step includes 
LAMP-2A expression and activity, since LAMP-2A role consists in the 
translocation of CMA target proteins within the lysosomes [85]. The 
third target accountable for a modulation of CMA is represented by 
PHLPP1, a phosphatase responsible for the direct regulation of CMA 
[88]. The expression of the genes encoding these proteins resulted to 
differentiate sensitive and resistant cells after TMZ treatment [200]. 
Sensitive cells show an overexpression of all the CMA-related genes 
while in resistant cells TMZ treatment reduced their expression. These 
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results confirmed the involvement of CMA in responsiveness to TMZ. 
CMA selective induction in sensitive cells has been confirmed by 
Western Blot analyses showing a statistically significant increase in 
LAMP-2A and HSC70 level after treatment with TMZ. In detail, only in 
U251 sensitive cells this increase is specific for the lysosomal fraction 
and involved also an already described CMA protein target, GAPDH 
confirming also the activation of this mechanism. Silencing 
experiments demonstrated that the lack of even one of the three CMA-
players would result in the abrogation of the entire CMA mechanism. 
In fact, we have demonstrated that the silencing of HSC70, PHLPP1 
or LAMP-2A is sufficient for abrogating CMA activity, driving U251 
sensitive cells toward a “resistant-like” behaviour. Notably, PHLPP1 
silencing not only was able to impair CMA activity but induced also a 
negative regulation of both LAMP-2A and HSC70 expression even 
after treatment with TMZ demonstrating its important regulatory role. 
These results confirmed the importance of CMA in GBM 
responsiveness to TMZ. On the other hand, in T98-resistant cells, 
CMA-related genes silencing has not brought any changes in 
responsiveness to TMZ; however, by the molecular side, PHLPP1 
silencing resulted in an overexpression of HSC70, probably due to the 
correspondent activation of a phosphorylation-dependent pathway 
which plays in HSC70 modulation, but further investigations of the 
whole mechanism need to be carried out. On the other hand, LAMP-
2A silencing abrogated the TMZ dependent HIF-1α down-regulation in 
U251 and was crucial in their switch, as regards apoptosis-related and 
EMT-related genes expression profile, after TMZ treatment toward a 
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“resistant-like” phenotype. CMA gene silencing in T98 did not provide 
any change in comparison to controls even after TMZ treatment. The 
only change was observed in the HIF-1α expression in LAMP-2A 
silenced cells after TMZ treatment. In fact, TMZ did not increase HIF-
1α expression level which remained at the control level. The same 
results were observed for EMT-related genes in the same condition 
and will need further studies going beyond the aim of this work.  
As for CMA-related genes, HIF-1α silencing has been accomplished 
[199], and showed important results being able to revert T98 resistant 
phenotype to a sensitive one, both for cell viability, HIF-1α activity and 
apoptosis-related gene expression pattern, demonstrating once again 
the pivotal role covered by this transcription factor which acts as switch 
between cell survival and cell death after TMZ treatment. Of note, the 
PX-478-mediated pharmacological inhibition of HIF-1α has confirmed 
the possibility of a pharmacological modulation driving TMZ 
responsiveness in resistant cells.  
Since the importance of CMA activity in mediating GBM 
responsiveness to TMZ, we focused our attention on the mechanisms 
involved in its activation such as oxidative stress. CMA, as reported 
from literature, is an important oxidative stress sensor, because it is 
involved in removing proteins which have been modified and damaged 
by ROS activity into the cells and this process hugely contributes to 
cell homeostasis modulation, by specific proteins selective 
degradation [78–80]; of note, LAMP-2A and HSC70, the  two CMA 
key-players, result to be up-regulated under oxidative stress [201]. In 
this work, a different cytoplasmic ROS content between sensitive and 
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resistant cells has been detected and reported, which is in relation to 
the different cell responsiveness to TMZ treatment and, as well, to 
CMA activity regulation. In detail, U251 TMZ-sensitive cells showed an 
increase in intracellular ROS after TMZ treatment while T98 resistant 
cells did not. The investigation on the role of the released ROS has 
demonstrated that ROS augmentation is strictly dependent to their 
mitochondrial release: in fact, MitoT (the mitochondrial ROS 
scavenger) exploitation abrogated their release in both cell lines. 
Moreover, the concurrent treatment of GBM cells with MitoT and TMZ, 
avoided the increase in cytoplasmic ROS in U251 sensitive cells and 
at the same time abrogated also cell cytotoxicity due to the drug. 
Further investigations will be accomplished in order to analyse in depth 
all those processes involved in this scenario: in fact, mitochondria, 
beyond to be an important cell ROS source, are key mediators of 
oxidative metabolism as well, and are even implicated in the apoptotic 
switch [202]. In the same sensitive cells (U251), MitoT treatment 
avoided TMZ-mediated reduction of HIF-1α activity and prevent the 
increase of pro-apoptotic gene expression after treatment. As regards 
CMA, mitochondrial ROS scavenger reverted TMZ-mediated 
expression pattern of the CMA-related genes both as single treatment 
and after TMZ treatment in U251 cells. Even in T98 cells, MitoT 
containing treatment induced a decrease in CMA related gene 
expression confirming the importance of ROS fluctuation for their 
expression. In line with these molecular results, also HIF-1α 
expression and activity and, as well, VEGF expression level have been 
modified by MitoT to a reciprocal modulation compared to that of 
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control cells sensitive to TMZ. Once again, HIF-1α activity and, in this 
example, VEGF transcript levels, might have been proposed as 
biomarkers for CMA activity determination and sensitivity to TMZ 
treatment. The absence of ROS fluctuation after TMZ treatment in 
U251 cells induced also a modification in EMT gene expression, 
changing the profile from an epithelial one to a mesenchymal one, 
confirming once more the crucial role of this ROS-related mechanism 
[83,91]. 
In this work, we have tried to elucidate all those mechanisms rounding 
cytoplasmic ROS increase after TMZ treatment; as we already 
mentioned, mitochondrial respiratory chain is the main ROS source, 
although cells have devised different processes to neutralise their 
intracellular damaging effect [92,99,100]. Through our data, we have 
been able to show that differences between U251 sensitive cells and 
the T98 resistant ones in ROS steady state level are related to an 
OXPHOS different activity, but that ROS increase after TMZ is not due 
to a to transitory change in OXPHOS activity. Neither OXPHOS 
complexes stability resulted to be altered by alkylating agent treatment 
and it is not accountable for the increase in ROS release due to TMZ 
treatment.  In different studies, chemotherapy resistance has been put 
in relation to the cellular anti-oxidant machinery [102], even in GBM 
context, and, associated to this notion, Glutathione Reductase, 
Catalase and SOD-2 activation  were evaluated and resulted to be 
higher in T98 cell line, supplying their contribution in mediating drug 
therapy resistance. A ROS detoxification machinery gene expression 
profile (GSH, GSS, GPX, CATALASE, SOD-2) confirmed the 
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differential involvement of this detox system between the two types of 
cell lines.  
Associated to the crucial role of this detox machinery in therapy 
resistance, several approaches for lowering this machinery activity 
have been reported in literature, as well as lots of treatments with the 
power, on the contrary, to augment oxidative stress in tumour cells (as, 
for instance, for Stupp protocol) [31,203]. In this work, an exogenously-
derived oxidative stress has been performed, to understand if an 
exogenously induced ROS fluctuation was able to activate the same 
pathways induced by TMZ-mediated ROS release in U251 cells and if 
it could be able to overcome detox systems activity in T98 ones. 
Hydrogen peroxide, H2O2, has been used for the chemically induced 
oxidative stress and a careful dose-response analysis, whose results 
have not been reported for better recapitulating this work, has been 
carried out; a 200 µM, named “mild”, and a 1 mM, defined “high”, 
concentrations have been chosen. In literature, several works have 
reported different doses of H2O2 administered in glioma cell lines [204–
206]: in particular, it seems that doses up to 200 µM did not 
significantly affect cell viability [207,208]. In a study of Zhang et al., it 
has been shown that treatment with H2O2 at a high dose (1 mM) for 24 
hours had the power to halve cell viability in U251 cell line, similarly to 
what occurred in cell viability assays in U251 cells treated with TMZ 
after 24 hours [208]. For this reason, we moved on with our analyses 
not only to confirm data reported in the Zhang’s work but also to 
evaluate a potential synergic effect due to the combination of H2O2 and 
TMZ administration in U251 e T98 cell lines. 
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Of note, H2O2 “high” dose had the power to activate, both as single 
treatment and in combination with TMZ, a pro-apoptotic expression 
pattern, to induce CMA-related gene expression, to reduce HIF-1α 
activity and to allow an epithelial-like expression profile in TMZ-
sensitive cells, as it occurred after TMZ treatment. For what concerns 
T98 resistant cell line, beyond the fact that “high” dose had the effect 
to decrease cell viability and induce pro-apoptotic gene expression, it 
had the capacity to upregulate also CMA gene expression and an 
epithelial-like profile of expression in EMT expression pattern. Notably, 
only H2O2 “high” dose in combination with TMZ was able to completely 
induce a sensitive-like expression pattern both in CMA related and 
EMT-related gene expression confirming TMZ as a reference drug for 
GBM treatment but only in combination with ROS level fluctuation. In 
summary, all these results put in light the increase in oxidative stress 
associated to TMZ treatment, as a fundamental step for activating 
CMA pathway, for down-modulating HIF-1α activity and, thereby, to 
allow TMZ to exert its toxic effect.  
The evaluation of such a combined treatment in an orthotopic model 
could help in improving new therapeutic approaches for resistant 
GBM. To set up this in vivo model, resistant cells already used for in 
vitro studies cannot be used since it has already been described that 
human T98 cells do not growth, after intracranial (i.c.) implantation, in 
murine models [196]. Thus, murine CT-2A cell line, which contrarily 
can be used for the production of orthotopic models [209], has been 
chosen in order to validate it as an in vivo model to assess the efficacy 
of ROS inducing treatments. In vitro CT-2A cell characterization 
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showed that these murine cells emulated the same response trend 
observed in T98 cells, both in cell viability and in HIF-1α activity after 
TMZ, different doses of H2O2 and in combined treatments, clearly 
confirming their resistant character. Moreover, Hif-1α silencing, as 
already reported for human GBM cell lines, was able to revert CT-2A 
resistant cells to a “sensitive-like” behaviour, supporting, even for the 
murine cells, the HIF-1α key role in mediating TMZ-responsiveness. 
CT-2A were used for the establishment of a TMZ-resistant murine 
orthotopic model. These experiments were performed during my stage 
at the University of Leeds in UK, where a fully equipped facility for non-
invasive imaging and radiotherapy for small animals is available. 
CT-2A cells were stereotaxically injected in syngeneic immune-
competent mice and tumour growth was monitored by MRI at different 
times after cell injection. Tumour growth rate was reproducible 
showing a good linearity during the considered time period. 
RT treatment showed that these tumours were sensitive to RT, as 
expected by in vitro tests after oxidative stress. Mice treated with 3 
fractions (5Gy each) had a statistically longer survival compared to 
untreated controls, confirming responsiveness to this oxidative stress 
inducing treatment. These results were confirmed by the reduction of 
tumour mass in treated mice, as detected by MRI.  
With the aim of identifying an imaging strategy able to describe the 
biological modifications occurring after treatment to responsive 
tumours, 18F-Fluciclovine-based PET imaging has been selected. In 
fact, it is strictly involved with primary GBM metabolism, that is, in turn, 
modulated by CMA activity.  
 
121 
 
This tracer is internalised by the cells in relation to the transport rate 
of specific amino acids, such as glutamine, through ASCT2 transporter 
[210,211]. This tracer has been already described for its ability in 
delineating tumour volume in GBM [182] but no data are available 
about its ability in reporting also GBM response to treatments. 
Preliminary results showed interestingly that RT was able to 
downregulate the expression of ASCT2 transporter as shown in IHC 
images. For this reason, we started implementing, in collaboration with 
ePIC imaging centre of the University of Leeds and the Blue Earth 
Diagnostics, the 18F-Fluciclovine producing company, a protocol for 
GBM non-invasive monitoring by PET with this tracer, in order to follow 
ASCT2 expression and activity in vivo, as a biomarker of 
responsiveness to an oxidative treatment able to non-invasively and 
repetitively describe biological and functional GBM features related to 
a specific metabolism. 
Herein, I have described the setting up of this imaging procedure by a 
first dynamic study of tracer biodistribution and localisation and a 
consecutive static analysis of tracer uptake by un-treated tumours. 
Results are encouraging since there is a statistically significant 
difference in the tumour to brain ratio in tumour bearing mice with a 
low background in controls and in surrounding tissues. 
Further studies will be performed in the next future to assess GBM 
response to radio- and radio-chemotherapies using CT-2A orthotopic 
model and 18F-Fluciclovine.   
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       CONCLUSIONS 
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In this research project, in conclusion, the findings have demonstrated 
the crucial role played by HIF-1α activity in supporting TMZ resistance, 
the importance of CMA activity in determining HIF-1α negative 
modulation after TMZ treatment. In fact, since HIF-1α can be degraded 
by Chaperone-Mediated Autophagy and TMZ induces autophagy, a 
relation between HIF-1α activity decrease, CMA activation and 
responsiveness to TMZ has been hypothesised. Through CMA-related 
(LAMP-2A, HSC70, PHLLP1) gene expression profile and Western 
Blot analyses, it has been demonstrated a pivotal CMA engagement 
in TMZ responsive cells. Moreover, this result has been confirmed by 
means of the gene silencing of CMA key-factors, LAMP-2A, HSC70 
and PHLPP1. The absence of even one of these proteins induced 
resistance in cells which were previously sensitive to TMZ, confirming 
CMA crucial role in mediating responsiveness to the alkylating agent.  
On the contrary, HIF-1α gene silencing reverted T98 phenotype from 
a previously resistant to a sensitive one, allowing TMZ to exert its 
cytotoxic effect even on these cells. Here it has been demonstrated 
also that PX-478 mediated pharmacological inhibition of HIF-1α 
activity is able to revert resistance to TMZ. Sensitivity and resistance 
to treatment have been identified by specific expression patterns of 
both apoptosis-, CMA- and EMT-related genes as well as by the kinetic 
of scratch closure. CMA induction can be activated by an increase of 
ROS cytoplasmic levels. In fact, responsiveness to TMZ is associated 
to a ROS release from the mitochondria resulting in a transitory 
increase of their cytoplasmic level and inducing CMA. The lack of this 
transitory increase was able to induce resistance to treatment in 
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previously sensitive cells. In the same way, the exogenous H2O2-
mediated increase in intracellular ROS levels has been able to restore 
not only CMA activation, but even a completely responsive profile in 
resistant cells. Transition from sensitivity to resistance and from 
resistance to sensitivity have been accompanied by parallel changes 
in gene expression pattern similar to those already reported. From 
these results, it is possible to assert that TMZ drives the burst of 
mitochondrial ROS in sensitive cells driving cell responsiveness, 
moreover the increase of ROS is crucial for CMA activation and then 
responsiveness. As regards in vivo results, data reported herein 
demonstrate that CT-2A derived orthotopic tumour bearing mice 
represent a good model of TMZ resistant tumours for the assessment 
of new treatments aimed at reverting resistance to TMZ, for example 
they resulted to be radio-responsive. Further assessment of new 
treatments will be helped by the use of a multimodal non-invasive 
imaging procedure based on the use of MRI and PET with 18F-
fluciclovine. In fact, 18F-fluciclovine has revealed to be a good 
radiotracer able to delineate tumour mass, consistently to tumours 
observed through MRI scans. Finally, preliminary IHC data of 
untreated and RT-treated mice brains have shown a decreased 
ASCT2 expression in RT-treated samples compared to the untreated 
controls. This finding provided a first molecular clue of a potential 
connection between CMA and the activity of this transporter, leading 
to new potential relations between CMA itself and tumour cell 
metabolism. 
As future perspectives:  
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- New methods are needed to better characterize GBM by non-
invasive functional imaging strategies. Mechanism underlying 18F-
Fluciclovine uptake will be studied to analyse if it could be in relation 
to CMA activity; 
- New therapeutic approaches will be tested in the orthotopic 
resistant model to evaluate the ability to overcome resistance by 
inhibiting HIF-1α or inducing CMA activity;  
- The importance of CMA will be studied also in relation to cell 
metabolism and the level of already identified miRNAs [212]. 
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